

1 **Title:** Emergency care interventions for pediatric severe acute respiratory infections in low- and middle-  
2 income countries: a systematic review and narrative synthesis  
3

4 **Authors:**

5 Pryanka Relan MD MPH CTropMed<sup>®1\*</sup> (0000-0002-9543-7891), Stephanie Chow Garbern MD MPH<sup>2\*</sup>  
6 (0000-0002-0919-2841), Gerard O'Reilly MBBS FACEM MPH MBIostat AStat PhD (0000-0001-5763-  
7 917X)<sup>3</sup>, Corey B Bills MD MPH<sup>4</sup> (0000-0002-3456-6008), Megan Schultz MD MA<sup>5</sup>(0000-0002-7286-  
8 0179), Sean Kivlehan MD MPH<sup>7</sup> (0000-0002-4857-4316), Indi Trehan MD MPH DTM&H CTropMed<sup>®6</sup>  
9 (0000-0002-3364-6858), Torben K Becker MD PhD<sup>8</sup> (0000-0002-5287-8056)  
10

11 *\*These authors contributed equally to this work.*  
12

- 13 1. Department of Emergency Medicine, Emory Healthcare Network, Atlanta, GA, USA
- 14 2. Department of Emergency Medicine, Warren Alpert Medical School of Brown University,  
15 Providence, RI, USA
- 16 3. Emergency and Trauma Centre, The Alfred, Melbourne, Australia; School of Public Health and  
17 Preventive Medicine, Monash University, Melbourne, Australia
- 18 4. Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO,  
19 USA
- 20 5. Department of Pediatrics, Medical College of Wisconsin, Milwaukee WI, USA
- 21 6. Departments of Pediatrics, Global Health, and Epidemiology, University of Washington, Seattle,  
22 WA, USA
- 23 7. Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, and Harvard  
24 Humanitarian Initiative, Cambridge, MA, USA
- 25 8. Department of Emergency Medicine, University of Florida, Gainesville, FL, USA  
26

27 **Corresponding Author:**

28 Pryanka Relan  
29 [pryanka.relan@gmail.com](mailto:pryanka.relan@gmail.com)  
30

31 **Registration:** PROSPERO (registration number CRD42020216117)  
32

33 **Key Words:** Emergency care; Low- and- middle-income countries (LMICs); severe acute respiratory  
34 illness (SARI); pneumonia; severe pneumonia; pediatrics; children; COVID-19  
35

36 **FUNDING:** The author(s) received no specific funding for this work.  
37

38 **ETHICAL APPROVAL:** Not required.  
39

40 **COMPETING INTERESTS:** The authors have declared that no competing interests exist.  
41

42 **ACKNOWLEDGEMENTS:** We thank Kelsey Sawyer of the Brown University Library for her  
43 assistance with development of the search strategies and retrieval. We thank the Global Emergency  
44 Medicine Literature Review (GEMLR) group and its editorial board for its support and dedication to this  
45 research.  
46

47 **DATA SHARING:** All relevant data are within the manuscript and its Supporting Information files.  
48

49 **ABSTRACT**

50

51 **Background:** Severe acute respiratory infections (SARIs) are the leading cause of pediatric death  
52 globally, particularly in low- and middle-income countries (LMICs). Given the potential rapid clinical  
53 decompensation and high mortality rate from SARIs, interventions that facilitate the early care of patients  
54 are critical to improving patient outcomes. The aim of this systematic review was to evaluate the impact  
55 of emergency care interventions on improving clinical outcomes of pediatric patients with SARIs in  
56 LMICs.

57

58 **Methods:** PubMed, Global Health, and Global Index Medicus electronic databases were searched to  
59 identify peer-reviewed clinical trials or studies with comparator groups published before November 2020.  
60 All studies which evaluated acute and emergency care interventions on clinical outcomes for children (29  
61 days to 19 years) with SARIs conducted in LMICs were included. Given the heterogeneity of  
62 interventions and outcomes, a narrative synthesis was performed. Bias was assessed using the Risk of  
63 Bias 2 and Risk of Bias in Non-Randomized Studies of Interventions.

64

65 **Results:** 20,583 studies were screened, with 99 meeting criteria for final inclusion. The most common  
66 conditions studied were pneumonia or acute lower respiratory infection (61.6%) and bronchiolitis  
67 (29.3%). The majority of studies evaluated medications (80.8%), followed by respiratory support (14.1%)  
68 and supportive care (5%). The strongest evidence of benefit was found for respiratory support  
69 interventions such as improved medical oxygen systems to decrease risk of death. Results were notably  
70 inconclusive on the utility of continuous positive airway pressure (CPAP). Mixed results were found for  
71 interventions for bronchiolitis, although possible benefit was found for hypertonic nebulized saline to  
72 decrease hospital length of stay. Early use of adjuvant treatments such as Vitamin A, D, and zinc for  
73 pneumonia and bronchiolitis did not appear to have convincing evidence of benefit on clinical outcomes.

74

75 **Conclusions:** While the burden of SARI in pediatric populations is high, few emergency care (EC)  
76 interventions have high quality evidence for benefit on clinical outcomes in LMICs. Respiratory support  
77 interventions have the strongest evidence for decreasing hospital length of stay and mortality and  
78 improvement of clinical status. Further research on the use of CPAP in diverse settings and populations  
79 is needed. A stronger evidence base for EC interventions for children with SARI, including metrics on  
80 the timing of interventions, is greatly needed.

81

## 82 INTRODUCTION

83 Acute respiratory infections (ARIs) are the leading cause of pediatric morbidity and mortality in low- and  
84 middle-income countries (LMICs), with pneumonia being the leading infectious cause of death in  
85 children under five years globally, causing over 800,000 deaths in 2019.<sup>1,2</sup> ARIs encompass a broad range  
86 of conditions from a simple “cold” or upper respiratory infection to bronchiolitis, pneumonia, respiratory  
87 involvement of measles and complications such as acute respiratory distress syndrome (ARDS)<sup>3,4</sup>. The  
88 World Health Organization (WHO) definition of Severe Acute Respiratory Infection (SARI) was  
89 developed in 2011 and updated in 2017 with the aim of standardizing surveillance for influenza-like  
90 illness (ILI) and was defined as “an acute respiratory infection with cough and fever which requires  
91 hospitalization.”<sup>5</sup>

92  
93 SARIs can be caused by a variety of pathogens, including viruses, bacteria, and parasites. Certain viral  
94 etiologies of SARI pose pandemic potential, such as pandemic influenza A (H1N1/09), and severe acute  
95 respiratory syndrome coronavirus 2 (SARS-CoV-2). Children in LMICs are among the most vulnerable to  
96 having poor outcomes from SARI due to inadequate immunization coverage, underlying conditions such  
97 as malnutrition, as well as limited access to health care resources such as medical oxygen, ventilators and  
98 relevant therapeutics. Emergency care (EC) interventions (i.e., those that provide or facilitate the early  
99 care of patients) are pivotal in improving outcomes for children with SARI.

100  
101 Despite advances in characterizing the etiologies, incidence, and factors contributing to SARIs,  
102 identifying which EC interventions are most effective in improving clinical outcomes in LMICs is critical  
103 to ensuring that limited available resources can be optimally targeted towards feasible and effective  
104 interventions. This systematic review's aim was to evaluate the impact of EC interventions on improving  
105 clinical outcomes of children with SARIs in LMICs.

## 106 METHODS

107 This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-  
108 analyses (PRISMA) guidelines and in collaboration with the Global Emergency Medicine Literature  
109 Review (GEMLR) groups<sup>6</sup> and registered on PROSPERO (CRD42020216117). As only published, de-  
110 identified data were used, this study was exempt from institutional review board approval<sup>7</sup>. A full  
111 description of the systematic review methods has been previously published in the concurrently  
112 conducted adult-focused review and are summarized below.<sup>7</sup>

### 113 *Search Strategy and Inclusion Criteria*

114  
115 PubMed, Global Health, and Global Index Medicus databases were searched November 2020 to January  
116 2021. Eligible studies included all randomized controlled trials (RCTs) and observational studies with a  
117 control group that evaluated short-term clinical outcomes and included each of three major search themes:  
118 SARI, emergency care interventions, and LMICs as defined by the 2020 World Bank Classification. Two  
119 independent reviewers screened each title and abstract using Covidence, with discrepancies resolved by a  
120 third reviewer; the same procedure was followed for full-text screening. Both pediatric and adult articles  
121 were included during initial screening, and later separated into pediatric (29 days to 19 years, as per WHO  
122 definitions) and adult-focused reviews, given the variations in SARI epidemiology and management  
123 between adults and children. Studies that focused on neonates (<28 days) only were excluded. Studies  
124 were screened based on the WHO SARI case definition criteria (i.e., regardless of whether the term  
125 “SARI” itself was used) due to a lack of consistent implementation of SARI surveillance across all LMIC  
126 contexts<sup>7</sup>. EC interventions were defined as relevant interventions initiated in the early period of care  
127 (within ~24 hours) without restrictions on setting. Only studies which evaluated patient-centric clinical  
128 outcomes such as mortality, need for intensive care unit (ICU) admission or mechanical ventilation,  
129 hospital length-of- stay (LOS), clinical severity, symptom duration or severity, were included (Appendix  
130 1).

131  
132

133 *Assessment of Risk of Bias*

134 Two authors independently assessed the included studies for risk of bias using the Cochrane Risk of Bias  
135 2 (RoB 2) tool for randomized trials and the Risk of Bias in Non-Randomized Studies (ROBINS-I) tool  
136 for observational studies; discrepancies were resolved by a third author. Risk of bias plots were created  
137 using *robvis* in R<sup>8</sup>.

138  
139 *Data Extraction and Analysis*

140 Two authors independently evaluated each article and extracted the data on a standardized form using  
141 Covidence, with discrepancies resolved by a third author (Appendix 2). Due to the heterogeneity of  
142 interventions, settings, and outcomes measured, requisite criteria for formal meta-analyses were not met,  
143 and therefore, a qualitative analysis and narrative synthesis was undertaken.

144  
145 **RESULTS**

146 The initial literature search yielded 25,180 studies, with 4,957 duplicates removed. After screening titles,  
147 abstracts, and full-text articles, 99 studies met inclusion criteria for further analysis (Figure 1). Pneumonia  
148 was the most common condition studied (52.5%), followed by bronchiolitis (29.3%, Table 1).  
149 Medications were the most common intervention type (80.8%) followed by respiratory support (14.1%).  
150 Most studies were conducted in general hospital/pediatric wards (72.7%), while only 18.1% of studies  
151 enrolled patients in emergency wards. Further characteristics of the studies included are shown in Table 1.  
152 Given the substantial number of studies, the results are presented by type of intervention, followed by the  
153 disease/condition studied (Table 2). Results obtained from the risk of bias assessment for RCTs and for  
154 observational studies are summarized in Figure 2 and 4, with individual risk of bias assessment for each  
155 study shown in Figures 3 and 5.

156  
157 Respiratory Support

158 Fourteen studies evaluated respiratory support interventions, including eight focused on oxygen delivery  
159 interventions and six on continuous positive airway pressure (CPAP).

160  
161 *Oxygen delivery, excluding CPAP*

162 Eight studies evaluated various oxygen delivery systems, six on pneumonia or ALRTI and two on  
163 undifferentiated acute respiratory distress. Duke et al. (2001) conducted a prospective cohort study in  
164 Papua New Guinea which found a decreased mortality (but not statistically significant) among children  
165 monitored with pulse oximetry and administered oxygen if SpO<sub>2</sub> < 85%. In another study by Duke et al.  
166 (2008), implementation of an oxygen administration guideline and oxygen concentrators was significantly  
167 associated with 35% lower risk of death. Mulondo et al. (Uganda) found that children with pneumonia  
168 treated with an oxygen-sparing nasal reservoir cannula had higher mean SpO<sub>2</sub> without adverse events,  
169 although other clinical outcomes were not measured in this small pilot RCT. Three RCTs among children  
170 with ALRTI were included; Muhe et al. (Ethiopia) conducted two RCTs (in 1997 and 1998) on oxygen  
171 administration via nasal catheter versus nasal prongs and found no differences in hypoxia or  
172 complications in children with ALRTI, although authors recommended the use of nasal prongs as needed  
173 and nose bleeding/ulceration was greater for nasal catheter use. In a stepped-wedge cluster randomized  
174 trial, Graham et al. (Nigeria) found decreased odds of death among children with ALRTI treated in  
175 hospitals after implementation of multifaceted standardized oxygen system package (improved oxygen  
176 equipment, clinical education, technical training/support, infrastructure support) over pulse oximetry  
177 introduction or baseline (usual care prior to introducing pulse oximetry), although benefit was not seen in  
178 children overall.

179  
180 Two studies evaluated interventions for undifferentiated respiratory distress; in a pre-post study, Hoffman  
181 et al. (South Africa) found that children treated during a period where high-flow nasal cannula was  
182 available may reduce need for transfers to higher level health facilities, although the study was

183 retrospective and underpowered for mortality benefit. Kumar et al. (India) evaluated several modes of  
184 oxygen delivery and found improved treatment of hypoxia among children administered oxygen via a  
185 headbox compared to face mask or nasal catheter.

186

#### 187 *Continuous Positive Airway Pressure (CPAP), including Bubble CPAP*

188 Two RCTs evaluated bubble CPAP (bCPAP) for pneumonia. Chisti et al. found that among children with  
189 pneumonia in Bangladesh, those who received bCPAP had lower mortality rate (4% vs. 15%; RR 0.25;  
190 95% CI 0.07-0.89) and lower treatment failure compared to low-flow oxygen therapy. However,  
191 McCollum et al. (Malawi) found that bCPAP was associated with higher hospital mortality (17% vs 11%;  
192 RR 1.52, 95% CI 1.02-2.27) compared with low flow oxygen in children, suggesting that bCPAP might  
193 carry risks not previously recognized. Three studies evaluated bCPAP for undifferentiated respiratory  
194 distress; an RCT by Wilson et al. (2013) in Ghana found decreased respiratory rate by 16 breaths/minute  
195 in children treated with immediate initiation (<1 hour) of CPAP, although no change in children who had  
196 CPAP delayed over an hour. Another RCT by Wilson et al. (2017) found no difference in mortality at two  
197 weeks in unadjusted analysis, however found a benefit with decreased mortality among children less than  
198 one year of age. Machen et al. (Malawi) evaluated bCPAP in a non-randomized study among children  
199 with undifferentiated acute respiratory distress in Malawi and found the best outcomes among children  
200 with bronchiolitis (92.9% survival), followed by pneumonia (53.3% survival), and PJP pneumonia  
201 (38.1% survival) although the study was limited by a lack of randomization and comparison of clinical  
202 outcomes. Lal et al. (India) found improved respiratory rate and clinical respiratory distress scores  
203 (Silverman-Anderson and Modified Pediatric Society of New Zealand scores) at one hour in children with  
204 bronchiolitis treated with nasal CPAP compared to oxygen through mask or hood in India.

205

#### 206 Supportive Care

207 Five studies evaluated supportive care interventions, including four on chest physiotherapy and one on  
208 steam therapy.

209

#### 210 *Physiotherapy*

211 Four RCTs evaluated the effectiveness of chest physiotherapy (PT); two for pneumonia and two for  
212 bronchiolitis<sup>9-12</sup>. Lukrafka et al. (Brazil) and Bohe et al. (Argentina) found no differences in severity  
213 score nor hospital LOS among children with pneumonia treated with chest PT. However, Abdelbasset et  
214 al. (Egypt) found faster time to clinical resolution of pneumonia and improvement in respiratory rate in  
215 children in the chest PT group and Gomes et al. (Brazil) found improvement in Wang respiratory score in  
216 infants with bronchiolitis treated with “new” chest physical therapy (with prolonged slow expiration and  
217 clearance rhinopharyngeal retrograde) or conventional chest PT compared with suction of upper airways  
218 alone.

219

#### 220 *Other supportive care interventions*

221 Singh et al. found that steam therapy had no benefit in children with pneumonia compared to standard of  
222 care although improvement was seen in children with bronchiolitis<sup>13</sup>.

223

#### 224 Medications – Antibiotics

225 Seventeen RCTs evaluated antibiotic-based interventions; nine on severe pneumonia, five on pneumonia,  
226 two RCTs on bronchiolitis and one on SARI generally.

227

#### 228 *Antibiotics for Severe Pneumonia*

229 Four RCTs evaluated oral amoxicillin versus parenteral antibiotics for severe pneumonia<sup>14-17</sup>. Three  
230 studies found oral amoxicillin versus injectable penicillin or ampicillin to have equal efficacy for children  
231 3-59 months of age<sup>14,15,17</sup>. In a sub-analysis of the trial conducted by Addo Yobo et al, Jeena et al. found



232 greater treatment failure with oral amoxicillin or parenteral penicillin at day 2 and day 14 among children  
233 with Human Immunodeficiency Virus (HIV) compared with children without HIV.

234  
235 Five RCTs evaluated various parenteral antibiotic regimens, four of which included chloramphenicol.  
236 Asghar et al. found greater treatment failure with chloramphenicol compared to ampicillin/gentamicin in  
237 children aged 2-59 months across seven LMICs. No difference in cure rates was found with ceftriaxone  
238 versus penicillin plus chloramphenicol (Cetinkaya et al.), mortality rates with benzylpenicillin plus  
239 chloramphenicol versus chloramphenicol alone (Shann et al.), or mortality rates and adverse outcomes in  
240 penicillin/gentamicin versus chloramphenicol (Duke et al.). Ribeiro et al. (Brazil) found hospital LOS and  
241 time to improvement of tachypnea was shorter with oxacillin/ceftriaxone versus amoxicillin/clavulanic  
242 acid in hospitalized children diagnosed with very severe pneumonia.

243  
244 *Antibiotics for Non-Severe Pneumonia*  
245 Four RCTs evaluate various antibiotic regimens for non-severe pneumonia. Straus et al. (Pakistan) found  
246 more treatment failures with trimethoprim-sulfamethoxazole (TMP-SMX) versus amoxicillin. Mulholland  
247 et al. (The Gambia) found no difference in treatment failure with chloramphenicol versus TMP-SMX for  
248 the treatment of malnourished children with community-acquired pneumonia. Hasali et al. (Malaysia)  
249 found shorter hospital LOS and time to switching to PO antibiotics with ampicillin-gentamicin  
250 combination compared to ampicillin alone. Brekhna et al. (Pakistan) found no difference in clinical  
251 response as defined as oxygen requirement, feeding ability, or tachypnea treated with amoxicillin versus  
252 cefuroxime versus clarithromycin, although this study was deemed to have a high risk of bias.

253  
254 *Antibiotics for Bronchiolitis*  
255 Kabir et al. (Bangladesh) found no benefit for parenteral ampicillin versus oral erythromycin versus no  
256 antibiotics on recovery of clinical symptoms in children with bronchiolitis; furthermore, children in the  
257 group given no antibiotics had a shorter hospital LOS compared with those who received antibiotics (3.7  
258 days vs 4.4 days). Pinto et al. (Brazil) found that azithromycin had no effect on the duration of  
259 hospitalization or oxygen requirement in children with bronchiolitis under one year.

260  
261 *Antibiotics for Undifferentiated SARI*  
262 Gamiño-Arroyo et al. evaluated the effectiveness of nitazoxanide for SARI in patients over 12 months of  
263 age in Mexico and found no difference in hospital LOS and no difference in viral shedding.

264  
265 Medications – Nebulized Treatments  
266 Seventeen studies evaluated nebulized treatments including 16 on bronchiolitis and one on croup.

267  
268 *Nebulized Treatments for Bronchiolitis*  
269 Six studies evaluated different concentrations of nebulized saline for children with bronchiolitis. Five  
270 RCTs evaluated hypertonic (3%) saline versus normal (0.9%) saline (NS); three studies found no benefit  
271 for 3% saline on clinical status or hospital LOS<sup>18-20</sup>. Two RCTs found benefit for 3% saline. However,  
272 Ejaz et al. (Pakistan) found greater reduction in respiratory score in the 3% saline group while Kumar et  
273 al. (India) found greater improvement in clinical severity, oxygen saturation at 24 hours, and shorter  
274 hospital length of stay with 3% saline. Soleimani et al. (Iran) compared three different concentrations of  
275 nebulized saline combined with salbutamol and found that in children 1-24 months those treated with 3%  
276 saline had shorter hospital LOS compared to those treated with 5% or NS.

277  
278 Two studies evaluated nebulized salbutamol versus epinephrine with mixed results; Ray et al. (India)  
279 found lower clinical severity score and respiratory rate for salbutamol over epinephrine, while Adhikari et  
280 al. (Nepal) found no difference in respiratory distress assessment instrument (RDAI) scores between those

281 treated with epinephrine versus salbutamol. Three studies evaluated bronchodilators versus nebulized  
282 saline, two of which found benefit for bronchodilators; Jawaria et al. (Pakistan) found that more children  
283 treated with salbutamol had a reduction in clinical bronchiolitis severity score compared to NS, although  
284 the study had high risk of bias; Khashabi et al. (Iran) found improved oxygen saturation, clinical score  
285 and respiratory rate in children treated with nebulized salbutamol or epinephrine compared to NS;  
286 however, Tinsa et al. (2009; Tunisia) found no difference in RDAI score or hospital LOS for nebulized  
287 terbutaline over saline. Shankar et al. (India) found no significant difference in clinical severity scores or  
288 hospital LOS for nebulized hypertonic saline versus epinephrine in India. Gadowski et al. (Egypt)  
289 compared nebulized albuterol, nebulized saline, orally administered albuterol, and orally administered  
290 placebo in Egypt and found no difference in outcomes among the four groups, except for an improvement  
291 in respiratory rate among those with history of recurrent wheezing. Farrah et al. (Pakistan) found no  
292 difference in clinical severity score with nebulized NAC versus salbutamol. Pukai et al. (Papua New  
293 Guinea) found that children less than 24 months with either bronchiolitis or pneumonia treated with NS  
294 versus standard of care had a greater reduction in respiratory distress score (RDS), and increase in pulse  
295 oximetry at 4 hours, and ability to be discharged from the ED.

296

### 297 *Nebulized Treatments for Croup*

298 Eghbali et al. (Iran) found a reduction in Westley clinical croup scores for nebulized epinephrine plus  
299 dexamethasone vs. nebulized saline plus dexamethasone in children aged six months to six years at 30,  
300 60, and 90 minutes, although this difference was not seen at 120 minutes.

301

### 302 Medications – Nutrients and Minerals

303 Seventeen studies evaluated nutrients and minerals (Vitamin A, C / E, D, and Zinc) as an intervention for  
304 treatment of children with acute lower respiratory tract infections (ALRTI), including pneumonia and  
305 bronchiolitis.

306

### 307 *Vitamin A for Acute Lower Respiratory Tract Infections (ALRTI), including Pneumonia*

308 Three RCTs evaluated a single high dose of vitamin A among hospitalized children with ALRTIs.  
309 Donnen et al. (Democratic Republic of the Congo) found no effect on mortality rates of a high-dose  
310 vitamin A versus low dose daily vitamin A on children with ALRTIs or diarrhea. Similarly, Kiolhede et  
311 al. (Guatemala) found no effect of adjuvant high dose vitamin A versus placebo on clinical parameters  
312 (e.g., respiratory rate, oxygen saturation), hospital LOS, or death. However, Julien et al. (Mozambique)  
313 found a shorter median hospital LOS (4 days vs. 3 days) among children treated with single high-dose  
314 vitamin A.

315

316 Six RCTs evaluated vitamin A for children with pneumonia<sup>21-26</sup>. Four RCTs evaluated high-dose vitamin  
317 A given on the day of admission and an additional dose on the subsequent day, three of which (conducted  
318 in Tanzania, Peru, and Brazil) found no effect on mortality, hospital LOS, or duration of pneumonia  
319 symptoms<sup>22,24,26</sup>. Furthermore, Stephensen et al. (Peru) additionally found greater adverse effects  
320 including lower oxygen saturation in children treated with high-dose vitamin A with pneumonia in Peru.  
321 However, Si et al. (Vietnam) found while there was no effect on hospital LOS in children with moderate-  
322 to-severe pneumonia overall, although a shorter hospital LOS among malnourished children (particularly  
323 females with very severe pneumonia) treated with high-dose vitamin A. Rodriguez et al. found no  
324 difference with treatment with moderate-dose vitamin A on duration of pneumonia in children with non-  
325 measles pneumonia in Ecuador. Lastly, Hussey et al. Focused on patients specifically with measles  
326 pneumonia and found lower mortality, shorter hospital LOS, and faster recovery in children who received  
327 vitamin A in South Africa

328

329 *Vitamin C and E for ALRTI, including pneumonia*

330 Mahalanabis et al. (India) evaluated Vitamin C and E together as adjunctive treatment for pneumonia in  
331 India and found no significant benefits of the combination therapy compared to placebo on tachypnea,  
332 fever, feeding or clinical status<sup>27</sup>.

333

334 *Vitamin D for ALRTI, including pneumonia*

335 Six RCTs evaluated the effect of vitamin D in children under five years with ALRTI or pneumonia, all of  
336 which found no benefit for vitamin D<sup>28-33</sup>. Somnath et al. (India), Gupta et al. (India), Dhungel et al.  
337 (Pakistan), Choudhary et al. (India), and Manaseki-Holland et al (Afghanistan) found no effect of a single  
338 high dose of vitamin D on hospital LOS or mortality in children under five years hospitalized with  
339 ALRTI. Similarly, Rajshekhar et al. (India) found no difference in time to resolution of pneumonia  
340 symptoms.

341

342 *Zinc for Bronchiolitis*

343 Two RCTs evaluated the effect of zinc on bronchiolitis in children under two years<sup>34,35</sup>. Ahadi et al. found  
344 that children in the treatment group had shorter hospital LOS ( $4.14 \pm 1.21$  versus  $4.64 \pm 1.2$  days;  
345  $p=0.016$ ) and less wheezing and rhinorrhea at 72 hours (16% vs 36%,  $p=0.023$ , 0 vs 12%,  $p=0.027$ ,  
346 respectively). Both found no difference in tachypnea, retractions, or cyanosis at 24 hours in the treatment  
347 versus control group; both studies were deemed to have high risk of bias.

348

349 *Zinc for Pneumonia*

350 The effect of zinc on pneumonia outcomes were evaluated in 15 RCTs<sup>36-50</sup>. Seven studies found no  
351 benefit for zinc treatment over placebo<sup>36,40,42,43,46,47,50</sup>. Five studies reported favorable outcomes for zinc;  
352 Brooks et al. (Bangladesh) found a shorter duration to resolution of pneumonia and a one-day shorter  
353 hospital LOS in the zinc group (72 vs 96 hours; HR (0.7; 95% CI 0.51-0.98), but no differences in  
354 resolution of chest indrawing or hypoxia; Heydarin et al. (Iran) found no benefit for zinc on hospital LOS  
355 but found reported shorter duration of fever at 24 and 36 hours and improvement in tachypnea at 36  
356 hours; Qasemzadeh et al. (Iran) and Rerksupphol et al. (Thailand) found shorter hospital LOS and time  
357 to resolution of clinical symptoms; Srinivasan et al. (Uganda) found decreased case fatality rate in  
358 children with severe pneumonia treated with zinc (4.0% vs. 11.9%), with greater effects in HIV-infected  
359 children. Conversely, Coles et al. (India) reported an increase in the median hospital LOS in the zinc  
360 group although the study had high risk of bias. Howie et al. (The Gambia) reported mixed outcomes with  
361 no difference found in time to resolution of symptoms, but marginal benefit for reduced time to resolution  
362 of chest indrawing and sternal retraction with zinc. Wadhwa et al. (India) found no benefit for zinc in  
363 their overall study population with severe pneumonia, however found benefit in stratified analysis among  
364 those with very severe pneumonia.

365

366 *Medications – Steroids*

367 Nine studies evaluated steroids; six on bronchiolitis, two on *Pneumocystis jirovecii* (PJP) pneumonia, and  
368 one on croup.

369

370 *Steroids for Bronchiolitis*

371 Six RCTs evaluated steroids for bronchiolitis, four of which found no benefit for steroids on hospital  
372 LOS, duration of symptoms or Respiratory Distress Assessment Instrument (RDAI) score<sup>51-54</sup>. However,  
373 Teeratakulpisarn et al. (Thailand) found decreased time to resolution of respiratory distress, duration of  
374 symptoms, duration of oxygen therapy, and hospital LOS in children treated with single IM  
375 dexamethasone, and Virk et al. (Pakistan) found decreased rhonchi on day 3 of admission and shorter  
376 hospital LOS with oral prednisolone, although this study had high concern for bias.

377



378 *Steroids for Croup, PJP pneumonia*

379 Sunboonnanonda et al. (Thailand) found children treated with parenteral dexamethasone treatment had  
380 lower croup scores at 48 hours, shorter LOS and lower incidence of endotracheal intubation compared to  
381 placebo. Green et al. (South Africa) and Newberry et al. (Malawi), found that children with HIV and PJP  
382 pneumonia treated with adjunctive steroids had lower mortality rates.

383  
384 Medications – Other

385 Dawood et al. found no effect for oseltamivir in children with influenza on LOS or work of breathing in  
386 Panama. Adinatha (Indonesia) et al. and Becina Paolo Gene et al. (Philippines) found no benefit for  
387 adjuvant probiotics in children with pneumonia. Shang et al. (China) found children with bronchiolitis  
388 treated with *Laggera pterodonta* (Traditional Chinese Medicine herb), more frequently met discharge  
389 criteria at 96 and 120 hours compared to control group.

390  
391 **DISCUSSION**

392  
393 Pediatric SARIs constitute a large burden of disease globally, with children in LMICs having the highest  
394 risk of mortality. Given the known association between delay of acute interventions with poor outcomes,  
395 we aimed to examine the current state of evidence on which emergency care interventions (those  
396 delivered in early period of care), have the strongest evidence for benefit on clinical outcomes. Patients  
397 generally present to a clinical provider without a specific disease or microbiologic diagnosis. Thus, our  
398 use of the SARI criteria as screening criteria was intentional in order to capture all studies including  
399 patients with undifferentiated respiratory illness. This strategy resulted in a broad array of interventions  
400 being included in the review, with most studies focused on medication interventions for children with  
401 pneumonia/ALRTIs or bronchiolitis (the most common respiratory conditions leading to hospitalization  
402 in children globally). Few interventions had strong evidence for benefit. The strongest evidence of  
403 benefit was found for respiratory support interventions. There was also strong evidence for lack of  
404 benefit of early use of adjuvant treatments such as Vitamin A, D and zinc on key clinical outcomes such  
405 as mortality and hospital length-of-stay for pneumonia and bronchiolitis.

406  
407 *Respiratory Support Interventions including Bubble CPAP*

408 The strongest evidence of benefit was found for respiratory support interventions. Strong oxygen  
409 delivery systems decrease risk of death, although results were inconclusive for the utility of CPAP  
410 specifically. Studies in this review show that respiratory support interventions should be implemented  
411 early, regardless of the final diagnosis: pneumonia, bronchiolitis, croup, other disease or undifferentiated.  
412 Particularly, interventions of equipment and supplies to deliver oxygen – concentrators, nasal devices and  
413 masks, must be readily available and combined with standardized training, technical support for  
414 maintenance of devices, pulse oximetry to monitor the patient, and guidelines for escalation and weaning  
415 of oxygen therapy. As a package, these interventions were found to decrease risk of death of a child with  
416 pneumonia by more than one third.

417  
418 In general, CPAP was found to be very beneficial in children less than 1 year of age and somewhat  
419 beneficial in children less than 5 years of age with pneumonia in LMICs. However, this intervention  
420 should be used with caution as it can be particularly cumbersome for small children and requires extra  
421 financial, material and human resources to maintain. A 2021 systematic review evaluated CPAP for  
422 children with respiratory distress in resource-limited settings and concluded that the existing evidence is  
423 inconclusive for CPAP efficacy against death and adverse events, compared with oxygen<sup>55</sup>. The authors  
424 also point out the variations in resource availability, level of care available (ICU vs ward), and illness  
425 severity make the context in which interventions were assessed important for extrapolating results.

426

427 *Steroids and Other Treatments for Bronchiolitis*

428 Steroids were not shown to be beneficial for bronchiolitis based on the findings in this review, but are  
429 beneficial for patients with HIV and PJP pneumonia, confirming earlier studies reflecting the same  
430 conclusions, including several systematic reviews finding a lack of convincing evidence for  $\beta$ 2 agonists  
431 and anticholinergics, adrenaline, corticosteroids, hypertonic saline, antibiotics, and chest physiotherapy in  
432 the acute management of bronchiolitis, which has been reflected in current clinical practice guidelines<sup>56</sup>.

433  
434 International treatment guidelines do not recommend nebulized saline for bronchiolitis, though a recent  
435 Cochrane review of articles from high- and low-income countries reported potentially improved outcomes  
436 (hospital LOS, clinical severity) based on low to moderate quality evidence<sup>57</sup>. In our review, one study  
437 with low risk of bias indicating nebulized NS may be beneficial for children with bronchiolitis<sup>58</sup>.  
438 However, the remaining eight studies that evaluated nebulized saline (either normal saline or hypertonic)  
439 with various comparators showed either no significant clinical outcome improvement<sup>59</sup> or had a high risk  
440 of bias associated with the study<sup>60</sup>.

441  
442 In this review we found articles reporting mixed directionality of support for nebulized salbutamol for  
443 bronchiolitis, but unidirectional support in articles comparing benefit of nebulized epinephrine for  
444 bronchiolitis and croup. Though there were concerns of bias in some of the studies, this intervention  
445 should be considered as a targeted question for future international guideline updates.

446  
447 *Early Administration of Adjuvant Nutrients and Minerals*

448 Vitamin A only proved to be beneficial for children with measles and vitamin D only helpful for  
449 preventing repeat pneumonia<sup>23,33</sup>. A dedicated review of the vitamin D intervention for ALRTI  
450 international guideline development could be considered. Vitamin A, C or D use in other etiologies of  
451 SARI were not supported by the evidence, whether due to negative studies or risk of bias.

452  
453 The two studies that evaluated zinc for bronchiolitis both had high risk of bias associated with them.  
454 While Farhad et al. found zinc to provide some clinical improvement, this has not been replicated, and  
455 zinc is not a recommended intervention for bronchiolitis by WHO guidelines<sup>61</sup>. However, among the  
456 sixteen articles that evaluated zinc for pneumonia, only one had high risk of bias associated. While most  
457 articles did not report significant clinical improvement in patients with pneumonia receiving zinc, and it is  
458 not a recommended standard intervention directly for pneumonia, zinc is an important micronutrient for a  
459 child's overall health and development and is often deficient in children who are dehydrated<sup>62,63</sup>. It is  
460 plausible that for the studies in which zinc was found to have an improvement in clinical outcomes, it  
461 may have been because children in those studies were more dehydrated than in others. Zinc remains an  
462 important acute care intervention for children who are deficient or at risk of dehydration, but not part of  
463 regular home or inpatient treatment of children with pneumonia.

464  
465 *Antibiotics*

466 Antibiotics for pneumonia continue to be a recommended treatment according to international  
467 guidelines<sup>61,64</sup>. Differentiation is made between diagnoses and treatments for pneumonia and severe  
468 pneumonia. Pneumonia is a form of ALRTI and treated with oral amoxicillin as outpatient unless the  
469 child has HIV infection. Severe pneumonia is recommended to be treated initially with intravenous (IV)  
470 or intramuscular (IM) ampicillin (or benzylpenicillin) and gentamicin, switched to IV/IM gentamicin and  
471 cloxacillin if no improvement in 48 hours, and ceftriaxone in the case of failure of first-line  
472 treatment<sup>61,64,65</sup>. All three studies evaluating antibiotic regimens for severe pneumonia in children without  
473 underlying complications found treatment with high-dose oral amoxicillin equivalent to IV/IM ampicillin  
474 and recommended an update to current WHO guidelines. All articles were deemed to have some risk of  
475 bias, but this similar finding in these studies was replicated in nine countries across the three studies. We  
476 agree that this recommendation should be re-evaluated in international guidelines. Replacing parenteral  
477 antibiotics with an oral regimen for severe pneumonia would save time and money from hospitalization,

478 including risk reduction of nosocomial infections. Ribeiro et al. showed that in comparison of IV  
479 oxacillin plus ceftriaxone versus of amoxicillin plus clavulanic acid for children (initiated IV and changed  
480 to oral after 48 hours) with very severe pneumonia, with outcomes showing significant improvement in  
481 tachypnea and decreased length of hospital stay in the amoxicillin group.

482  
483 Chloramphenicol does not appear to be a viable option for severe pneumonia treatment based on the  
484 studies evaluated in this review and is not generally included as part of usual care for this illness<sup>61</sup>.  
485 Studies evaluating different antibiotic regimens for non-severe pneumonia revealed that cotrimoxazole is  
486 not a reliable first-line choice, and gentamicin is not required as a first line for community acquired  
487 pneumonia. Other regimens did not reveal a superior choice.

488  
489 Multiple studies confirmed a lack of benefit antibiotics for treatment of viral-mediated illness (including  
490 bronchiolitis) supporting recommendations that antibiotics should not be used for viral respiratory  
491 infection. Gamino-Arroyo's work evaluating nitazoxanide in addition to standard of care in children over  
492 1 year of age in Mexico for influenza-like illness, as well as Kabir et al. and Pinto et al.'s work on  
493 evaluating antibiotics for viral bronchiolitis, are important additions to the literature supporting lack of  
494 effectiveness of antibiotics against viral illnesses, both in terms of lack of symptom improvement and in  
495 viral dynamics.

#### 496 497 *Critical Gaps in the Literature*

498 Very few studies included populations with undifferentiated respiratory distress, and only one study used  
499 the case definition of SARI as its inclusion criteria. Given that EC interventions often must be  
500 implemented prior to a formal clinical diagnosis, this review highlights a critical need for future studies to  
501 enroll children with undifferentiated respiratory infections. The majority (>80%) of the included studies  
502 evaluated medication interventions, with relatively few studies on other interventions, such as respiratory  
503 support. We also found that very few studies explicitly reported on the timing of interventions, with most  
504 studies either conducted outside of dedicated emergency wards or clearly during the earliest periods of  
505 care when the patient's respiratory illness may be most amenable to acute interventions (e.g., shortly after  
506 presentation to a health facility, such as in triage or a dedicated emergency unit).

507  
508 This review has several limitations. Limitations related to the development of the review and overall  
509 characteristics of results are previously described<sup>7</sup>. In particular and to emphasize, given that emergency  
510 care is not well defined across the world especially in LMICs and emergency care is often delivered  
511 outside of a dedicated emergency unit, we agreed on including any "emergent and early intervention"  
512 deemed appropriate by the reviewers, specifically including those focused on community-acquired  
513 pneumonia or discussing interventions beginning in the first 24 hours of hospitalization. As timing of  
514 interventions may greatly impact the trajectory of disease progression, future research on early and  
515 emergency care of patients must report timing and location of intervention in publications. Furthermore,  
516 inclusion of specific elements in the search strategy such as "bronchiolitis", "croup" or "children" may  
517 have supported a smaller search result and tailored review.

#### 518 519 **CONCLUSION**

520  
521 Despite few studies specifically evaluating patients in dedicated emergency units, or those with  
522 undifferentiated SARIs, a wide variety of interventions that may impact the early care of children was  
523 found. While the burden of SARI in pediatric populations is high, few interventions were found to have  
524 high quality evidence for benefit on clinical outcomes in LMICs, with respiratory support interventions  
525 having the strongest evidence for decreasing symptom duration and hospital length of stay, although with  
526 inconclusive evidence for bubble CPAP. Despite relatively few studies focused on non-medication  
527 interventions, the strongest evidence of benefit was found for respiratory support interventions such as  
528 improved oxygen delivery systems to decrease risk of death. Mixed results were found for interventions

529 for bronchiolitis, although possible benefit was found for hypertonic nebulized saline to decrease hospital  
530 length of stay. Early use of adjuvant treatments such as Vitamin A, D and zinc did not appear to have  
531 convincing evidence of benefit on clinical outcomes in pneumonia and bronchiolitis. Further research  
532 evaluating the effect of targeted and time sensitive interventions for children with undifferentiated severe  
533 respiratory infections is greatly needed.  
534

535 **REFERENCES**

- 536
- 537 1. Acute respiratory infections. 1990.
- 538 2. Evaluation IfHMa. Global Burden of Disease. 2019.
- 539 3. Orloff KE, Turner DA, Rehder KJ. The Current State of Pediatric Acute Respiratory  
540 Distress Syndrome. *Pediatr Allergy Immunol Pulmonol*. Jun 01 2019;32(2):35-44.  
541 doi:10.1089/ped.2019.0999
- 542 4. Jamison DT, Breman JG, Measham AR, et al. Disease Control Priorities in Developing  
543 Countries. 2006.
- 544 5. Fitzner J, Qasmieh S, Mounts AW, et al. Revision of clinical case definitions: influenza-  
545 like illness and severe acute respiratory infection. *Bull World Health Organ*. Feb 01  
546 2018;96(2):122-128. doi:10.2471/BLT.17.194514
- 547 6. Global Emergency Medicine Literature Review Group.
- 548 7. Garbern SC, Relan P, O'Reilly GM, et al. A systematic review of acute and emergency  
549 care interventions for adolescents and adults with severe acute respiratory infections including  
550 COVID-19 in low- and middle-income countries. *J Glob Health*. Nov 08 2022;12:05039.  
551 doi:10.7189/jogh.12.05039
- 552 8. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and  
553 Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods*. Jan 2021;12(1):55-  
554 61. doi:10.1002/jrsm.1411
- 555 9. Abdelbasset W, Elnegamy T. Effect of chest physical therapy on pediatrics hospitalized  
556 with pneumonia. *International Journal of Health and Rehabilitation Science*. 2015;4(4):219-226.
- 557 10. Lukrafka JL, Fuchs SC, Fischer GB, Flores JA, Fachel JM, Castro-Rodriguez JA. Chest  
558 physiotherapy in paediatric patients hospitalised with community-acquired pneumonia: a  
559 randomised clinical trial. *Archives of Disease in Childhood*. 2012;97(11):967-971.
- 560 11. Bohe L, Ferrero ME, Cuestas E, Polliotto L, Genoff M. Indicacion de la fisioterapia  
561 respiratoria convencional en la bronquiolitis aguda. *Medicina (BAires)*. 2004;64(3):198-200.
- 562 12. Gomes ÉLFD, Postiaux G, Medeiros DRL, Monteiro KKDS, Sampaio LMM, Costa D.  
563 Chest physical therapy is effective in reducing the clinical score in bronchiolitis: randomized  
564 controlled trial. *Braz j phys ther (Impr)*. 2012;16(3):241-247.
- 565 13. Singh M, Singhi S, Walia BN. Evaluation of steam therapy in acute lower respiratory  
566 tract infections: a pilot study. *Indian Pediatr*. 1990;
- 567 14. Addo-Yobo E, Chisaka N, Hassan M, et al. Oral amoxicillin versus injectable penicillin  
568 for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency  
569 study. *Lancet*. 2004;364(9440):1141-8. doi:10.1016/s0140-6736(04)17100-6
- 570 15. Hazir T, Fox LM, Nisar YB, et al. Ambulatory short-course high-dose oral amoxicillin  
571 for treatment of severe pneumonia in children: a randomised equivalency trial. *Lancet*.  
572 2008;371(9606):49-56. doi:10.1016/s0140-6736(08)60071-9
- 573 16. Jeena P, Thea DM, MacLeod WB, et al. Failure of standard antimicrobial therapy in  
574 children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia. *Bull*  
575 *World Health Organ*. 2006;84(4):269-75. doi:10.2471/blt.04.015222
- 576 17. Agweyu A, Gathara D, Oliwa J, et al. Oral amoxicillin versus benzyl penicillin for severe  
577 pneumonia among kenyan children: a pragmatic randomized controlled noninferiority trial. *Clin*  
578 *Infect Dis*. 2015;60(8):1216-24. doi:10.1093/cid/ciu1166
- 579 18. Ojha AR, Mathema S, Sah S, Aryal UR. A comparative study on use of 3% saline versus  
580 0.9% saline nebulization in children with bronchiolitis. *J Nepal Health Res Counc*.  
581 2014;12(26):39-43.



- 582 19. Sharma BS, Gupta MK, Rafik SP. Hypertonic (3%) saline vs 0.9% saline nebulization for  
583 acute viral bronchiolitis: a randomized controlled trial. *Indian pediatrics*. 2013;50(8):743-747.
- 584 20. Tinsa F, Abdelkafi S, Bel Haj I, et al. A randomized, controlled trial of nebulized 5%  
585 hypertonic saline and mixed 5% hypertonic saline with epinephrine in bronchiolitis. *Tunis Med*.  
586 2014;92(11):674-7.
- 587 21. Si NV, Grytter C, Vy NN, Hue NB, Pedersen FK. High dose vitamin A supplementation  
588 in the course of pneumonia in Vietnamese children. *Acta Paediatr*. 1997;86(10):1052-5.  
589 doi:10.1111/j.1651-2227.1997.tb14805.x
- 590 22. Fawzi WW, Mbise RL, Fataki MR, et al. Vitamin A supplementation and severity of  
591 pneumonia in children admitted to the hospital in Dar es Salaam, Tanzania. *Am J Clin Nutr*.  
592 1998;68(1):187-92. doi:10.1093/ajcn/68.1.187
- 593 23. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe  
594 measles. *N Engl J Med*. 1990;323(3):160-4. doi:10.1056/nejm199007193230304
- 595 24. Nacul LC, Kirkwood BR, Arthur P, Morris SS, Magalhães M, Fink MC. Randomised,  
596 double blind, placebo controlled clinical trial of efficacy of vitamin A treatment in non-measles  
597 childhood pneumonia. *Bmj*. 1997;315(7107):505-10. doi:10.1136/bmj.315.7107.505
- 598 25. Rodríguez A, Hamer DH, Rivera J, et al. Effects of moderate doses of vitamin A as an  
599 adjunct to the treatment of pneumonia in underweight and normal-weight children: a  
600 randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr*. 2005;82(5):1090-6.  
601 doi:10.1093/ajcn/82.5.1090
- 602 26. Stephensen CB, Franchi LM, Hernandez H, Campos M, Gilman RH, Alvarez JO.  
603 Adverse effects of high-dose vitamin A supplements in children hospitalized with pneumonia.  
604 *Pediatrics*. 1998;101(5):E3. doi:10.1542/peds.101.5.e3
- 605 27. Mahalanabis D, Jana S, Shaikh S, et al. Vitamin E and vitamin C supplementation does  
606 not improve the clinical course of measles with pneumonia in children: a controlled trial. Oxford;  
607 UK: Oxford University Press; 2006. p. 302-303.
- 608 28. Somnath SH, Biswal N, Chandrasekaran V, Jagadisan B, Bobby Z. Therapeutic effect of  
609 vitamin D in acute lower respiratory infection: A randomized controlled trial. *Clin Nutr ESPEN*.  
610 2017;20:24-28. doi:10.1016/j.clnesp.2017.02.003
- 611 29. Choudhary N, Gupta P. Vitamin D supplementation for severe pneumonia--a randomized  
612 controlled trial. *Indian Pediatr*. 2012;49(6):449-54. doi:10.1007/s13312-012-0073-x
- 613 30. Gupta P, Dewan P, Shah D, et al. Vitamin D Supplementation for Treatment and  
614 Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo  
615 Controlled Trial. *Indian Pediatr*. 2016;
- 616 31. Rajshekhar CS, Vanaki R, Badakali AV, Pol RR, Yelamali BC. Efficacy of vitamin D  
617 supplementation in the treatment of severe pneumonia in children aged less than five years. *Int J*  
618 *Contemp Pediatr*. 2016;3(1):96-99.
- 619 32. Dhungel A, Alam MS. Efficacy of vitamin D in children with pneumonia: a randomized  
620 control trial study. 2016;3
- 621 33. Manaseki-Holland S, Qader G, Isaq Masher M, et al. Effects of vitamin D  
622 supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial.  
623 *Trop Med Int Health*. 2010;15(10):1148-55. doi:10.1111/j.1365-3156.2010.02578.x
- 624 34. Ahadi A, Mirzarahimi M, Barak M, Ahari SS, Reyhanian M. Comparing the effect of  
625 zinc gluconate and placebo in the treatment of tachypnea, dyspnea and fever in children aged 2  
626 to 23 months with acute bronchiolitis. 2020;7

- 627 35. Farhad H, Fatemeh B, Mohammadkhaje D, Hamidreza K, Mohammadnasir H. <The>  
628 role of zinc sulfate in acute bronchiolitis in patients aged 2 to 23 months. 2011. p. 231-234.
- 629 36. Bose A, Coles CL, Gunavathi, et al. Efficacy of zinc in the treatment of severe  
630 pneumonia in hospitalized children <2 y old. *Am J Clin Nutr*. 2006;83(5):1089-96; quiz 1207.  
631 doi:10.1093/ajcn/83.5.1089
- 632 37. Brooks WA, Yunus M, Santosham M, et al. Zinc for severe pneumonia in very young  
633 children: double-blind placebo-controlled trial. *Lancet*. 2004;363(9422):1683-8.  
634 doi:10.1016/s0140-6736(04)16252-1
- 635 38. Coles CL, Bose A, Moses PD, et al. Infectious etiology modifies the treatment effect of  
636 zinc in severe pneumonia. *Am J Clin Nutr*. 2007;86(2):397-403. doi:10.1093/ajcn/86.2.397
- 637 39. Howie S, Bottomley C, Chimah O, et al. Zinc as an adjunct therapy in the management of  
638 severe pneumonia among Gambian children: randomized controlled trial. *J Glob Health*.  
639 2018;8(1):010418. doi:10.7189/jogh.08.010418
- 640 40. Fataki MR, Kisenge RR, Sudfeld CR, et al. Effect of zinc supplementation on duration of  
641 hospitalization in Tanzanian children presenting with acute pneumonia. *J Trop Pediatr*.  
642 2014;60(2):104-11. doi:10.1093/tropej/fmt089
- 643 41. Heydarian F, Nasiri M, Nakhaei AA, Ahanchian H, Ghahremani S, Haghbin A.  
644 Investigating the effect of prescribing zinc sulfate on improving the clinical symptoms of  
645 pneumonia in 2-59-month-old children. *International Journal of Pediatrics*. 2020;8(11):12471-  
646 12479.
- 647 42. Laghari GS, Hussain Z, Taimur M, Jamil N. Therapeutic Role of Zinc Supplementation  
648 in Children Hospitalized with Pneumonia. *Cureus*. 2019;11(4):e4475. doi:10.7759/cureus.4475
- 649 43. Mahalanabis D, Chowdhury A, Jana S, et al. Zinc supplementation as adjunct therapy in  
650 children with measles accompanied by pneumonia: a double-blind, randomized controlled trial.  
651 *Am J Clin Nutr*. 2002;76(3):604-7. doi:10.1093/ajcn/76.3.604
- 652 44. Qasemzadeh MJ, Fathi M, Tashvighi M, et al. The effect of adjuvant zinc therapy on  
653 recovery from pneumonia in hospitalized children: a double-blind randomized controlled trial.  
654 *Scientifica (Cairo)*. 2014;2014:694193. doi:10.1155/2014/694193
- 655 45. Rerksuppaphol L, Rerksuppaphol S. Efficacy of Adjunctive Zinc in Improving the  
656 Treatment Outcomes in Hospitalized Children with Pneumonia: A Randomized Controlled Trial.  
657 *J Trop Pediatr*. 2020;66(4):419-427. doi:10.1093/tropej/fmz082
- 658 46. Semp<sup>√</sup>©rtogui F, Estrella B, Rodr<sup>√</sup>≠guez O, et al. Zinc as an adjunct to the treatment of  
659 severe pneumonia in Ecuadorian children: a randomized controlled trial. *Am J Clin Nutr*.  
660 2014;99(3):497-505. doi:10.3945/ajcn.113.067892
- 661 47. Shah GS, Dutta AK, Shah D, Mishra OP. Role of zinc in severe pneumonia: a  
662 randomized double blind placebo controlled study. *Ital J Pediatr*. 2012;38:36. doi:10.1186/1824-  
663 7288-38-36
- 664 48. Srinivasan MG, Ndeezi G, Mboijana CK, et al. Zinc adjunct therapy reduces case fatality  
665 in severe childhood pneumonia: a randomized double blind placebo-controlled trial. *BMC Med*.  
666 2012;10:14. doi:10.1186/1741-7015-10-14
- 667 49. Wadhwa N, Chandran A, Aneja S, et al. Efficacy of zinc given as an adjunct in the  
668 treatment of severe and very severe pneumonia in hospitalized children 2-24 mo of age: a  
669 randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr*. 2013;97(6):1387-94.  
670 doi:10.3945/ajcn.112.052951
- 671 50. Valentin<sup>er</sup>-Branth P, Shrestha PS, Chandyo RK, et al. A randomized controlled trial of  
672 the effect of zinc as adjuvant therapy in children 2-35 mo of age with severe or nonsevere

- 673 pneumonia in Bhaktapur, Nepal. *Am J Clin Nutr.* 2010;91(6):1667-74.  
674 doi:10.3945/ajcn.2009.28907
- 675 51. Aamer Q, Humayun K, Afsheen M. Comparison of mean duration of bronchiolitis in  
676 children receiving standard treatment with and without intravenous steroid. 2015. p. 5-9.
- 677 52. Ahmad Omair V. Comparison of conventional treatment along with prednisolone and  
678 conventional treatment alone in bronchiolitis. 2014. p. 160-163.
- 679 53. Mesquita M, Castro-Rodríguez JA, Heinichen L, Fariña E, Iramain R. Single oral dose of  
680 dexamethasone in outpatients with bronchiolitis: a placebo controlled trial. *Allergol*  
681 *Immunopathol (Madr).* 2009;37(2):63-7. doi:10.1016/s0301-0546(09)71106-1
- 682 54. Zhang L, Ferruzzi E, Bonfanti T, et al. Long and short-term effect of prednisolone in  
683 hospitalized infants with acute bronchiolitis. *J Paediatr Child Health.* 2003;39(7):548-51.  
684 doi:10.1046/j.1440-1754.2003.00212.x
- 685 55. Sessions KL, Smith AG, Holmberg PJ, et al. Continuous positive airway pressure for  
686 children in resource-limited settings, effect on mortality and adverse events: systematic review  
687 and meta-analysis. *Arch Dis Child.* Jun 2022;107(6):543-552. doi:10.1136/archdischild-2021-  
688 323041
- 689 56. Hartling L, Fernandes RM, Bialy L, et al. Steroids and bronchodilators for acute  
690 bronchiolitis in the first two years of life: systematic review and meta-analysis. *BMJ.* Apr 06  
691 2011;342:d1714. doi:10.1136/bmj.d1714
- 692 57. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline  
693 solution for acute bronchiolitis in infants. *Cochrane Database Syst Rev.* 12 21  
694 2017;12:CD006458. doi:10.1002/14651858.CD006458.pub4
- 695 58. Pukai G, Duke T. Nebulised normal saline in moderate acute bronchiolitis and  
696 pneumonia in a low- to middle-income country: a randomised trial in Papua New Guinea.  
697 *Paediatr Int Child Health.* 2020;40(3):171-176. doi:10.1080/20469047.2020.1725338
- 698 59. !!! INVALID CITATION !!! 32-38;
- 699 60. A PK, Rajarathinam I, Gowdra A. Comparative evaluation of nebulised 3% saline versus  
700 nebulised 0.9% saline in the treatment of acute bronchiolitis. 2019;6
- 701 61. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common  
702 Childhood Illnesses. 2013.
- 703 62. Wapnir RA. Zinc deficiency, malnutrition and the gastrointestinal tract. *J Nutr.* May  
704 2000;130(5S Suppl):1388S-92S. doi:10.1093/jn/130.5.1388S
- 705 63. Roy SK, Tomkins AM, Ara G, et al. Impact of zinc deficiency on vibrio cholerae  
706 enterotoxin-stimulated water and electrolyte transport in animal model. *J Health Popul Nutr.*  
707 Mar 2006;24(1):42-7.
- 708 64. UNICEF. *Standard Treatment Manual for Children: A manual for health workers.* 4th  
709 ed. 2017.
- 710 65. Tong N. Background Paper 6.22  
711 Pneumonia: Update on 2004 Background Paper. Priority Medicines for Europe and the World  
712 "A Public Health Approach to Innovation": World Health Organization; 2013.  
713  
714

715 **Table 1. Characteristics of studies (n=99).**  
716

	<b>Number of studies (%) (N=99)</b>
<b>Type of study</b>	
Randomized controlled trial	91 (91.9)
Observational, prospective	4 (4.0)
Observational, retrospective	3 (3.0)
Non-randomized trial	1 (1.0)
<b>World Bank income group</b>	
Lower middle-income only	60 (60.6)
Upper middle-income only	23 (23.2)
Low-income only	12 (12.1)
Mixed: LIC, LMIC, UMIC	4 (4.0)
<b>World Health Organization region</b>	
Southeast Asian	25 (25.3)
Eastern Mediterranean	24 (24.2)
African	21 (21.2)
American	14 (14.1)
Western Pacific	12 (12.1)
Mixed	2 (2.0)
European	1 (1.0)
<b>Disease/condition</b>	
Pneumonia	52 (52.5)
Bronchiolitis	29 (29.3)
Acute lower respiratory tract infection	9 (9.1)
Undifferentiated acute respiratory distress	5 (5.1)
Croup	2 (2.0)
Influenza	1 (1.0)
Severe Acute Respiratory Illness	1 (1.0)
<b>Intervention</b>	
Medications	80 (80.8)
Respiratory support	14 (14.1)
Supportive care	5 (5.0)
<b>Location where study took place</b>	
Emergency department	18 (18.1)
Hospital ward	72 (72.7)
Intensive care unit	3 (3.0)
Outpatient / Other / Not specified	6 (6.0)

**Table 2. Summary of Findings – Respiratory Support and Supportive Care.**

Study ID	Country	Design	Age	Study Aim	N	Setting	Intervention	Key Findings	RoB
<b>Respiratory support (n=14)</b>									
<b>Oxygen delivery system (n=8)</b>									
<b>Pneumonia and ALRTI</b>									
Duke 2001	Papua New Guinea	Prospective cohort	1-59 months	To investigate the severity and duration of hypoxemia in children with severe or very severe pneumonia, to study the predictive value of clinical signs for severity of hypoxemia, the predictive value of SpO <sub>2</sub> and other variables for mortality	961	Hospital Ward	Oxygen monitoring protocol (admission and daily) with administration of O <sub>2</sub> if SaO <sub>2</sub> <85%	The mortality rate ratio between this retrospective control group and the 703 children managed with pulse oximetry was 0.65 (95%CI 0.41,1.02, Fisher's exact test, P= 0.07).	Moderate
Duke 2008	Papua New Guinea	Pre-/Post-Study	Not stated	To evaluate the effect of an improved oxygen system on death rate in children with pneumonia in Papua New Guinea	11,291	Hospital Ward	Access to Oxygen concentrators, guideline for O <sub>2</sub> according to SpO <sub>2</sub> and signs, standardized O <sub>2</sub> -weaning guideline	Risk of death for a child with pneumonia was 35% lower than was that before the project began (risk ratio 0.65 [0.52,0.78], p<0.0001)	
Graham 2019	Nigeria	RCT	<15 years	To evaluate the effects of an improved oxygen system on mortality and clinical practices for hospitalized children with acute lower respiratory tract infection	48,976	Hospital Ward	Multifaceted oxygen system at hospital level 1) standardized oxygen equipment; 2) clinical education and support; 3) technical training and support, and 4) infrastructure and systems support versus pulse oximetry introduction versus baseline	No association with mortality for oxygen system versus pulse oximetry for children with ALRTI (aOR1.09; 95% CI 0.50-2.41; p=0.824). Increased risk of death for neonates overall (aOR1.45; 95% CI 1.04-2.00; p=0.026) but not preterm/low-birth-weight neonates (aOR1.30; 95%CI 0.76-2.23; p=0.366). In secondary analyses, pulse oximetry associated with lower odds of death from Vaseline for children with ALRI (aOR 0.33; 95%CI 0.12-0.92; p=0.035) but not for children, preterm neonates, or neonates overall.	Some
Mulondo 2020	Uganda	RCT	<59 months	To design and optimize an oxygen-sparing nasal reservoir cannula (OSNRC) and collect pilot data on its safety and efficacy among Ugandan	16	Hospital Ward	Oxygen via OSNRC (oxygen sparing nasal reservoir cannula) for 1 hour versus	There were no significant differences between OSNRC and SNC with respect to clinical adverse events, lactate levels, pH, and SpO <sub>2</sub> . The OSNRC group had a higher mean SpO <sub>2</sub> than the SNC group (adjusted mean difference, 1.4, 95% confidence	Some



				children hospitalized with hypoxemic pneumonia.			standard nasal cannula	interval 1.1 to 1.8), showing oxygen delivery enhancement	
Muhe 1997	Ethiopia	RCT	0.5-60 months	To compare the frequency of complications when nasopharyngeal catheters or nasal prongs are used to deliver oxygen to children with ALRI.	121	Hospital Ward	Oxygen delivery by nasopharyngeal catheter vs nasal prongs	No difference in hypoxemic episodes. e.g., Mean number of hypoxemic episodes of 2.97 (catheter) vs 2.39 (prongs) for first 24h. No differences in nasal blockage, mucus production or nursing effort required. Ulceration/bleeding of nose more common in catheter group (19.7 versus 6.7%, p<0.05).	Some
Muhe 1998	Ethiopia	RCT	0.5-60 months	To estimate the frequency of complications when nasal catheters or nasal prongs are used to deliver oxygen to children	99	Hospital Ward	Nasal catheter vs nasal prongs for oxygen delivery	No significant differences in complications, mean flow rate or mean episodes of hypoxemia between the control group and the treatment group (2 vs 1; 0.95 vs 0.9; 3 vs 2; no p values reported). Children in the treatment group had more mucus production on Days 1 and 2 than the control group (37% and 29% vs 13% and 11%, p < 0.05). Amount of nursing time required was significantly higher for the treatment group than the control group (max 22 minutes vs 14 minutes, p<0.05).	High
<i>Acute respiratory distress</i>									
Hoffman 2019	South Africa	Pre-post	<13 years	To describe the outcomes of and adverse events related to HFNC in the first year of its use in a level 2 (L2) general pediatric ward, and to compare these outcomes with those of a historical cohort when HFNC was unavailable.	120	Hospital Ward	HFNC oxygen <10 kg: 2.0 L/kg/min and >10 kg: 2.0 L/kg/min for the first 10 kg plus 0.5 L/kg/min for each kg above 10 kg, with a maximum flow rate of 50 L/min	No difference in mortality rate (3.0% vs. 3.7% pre-HFNC and HFNC availability groups) although underpowered for mortality outcome. In the pre-HFNC group 6.5% were transferred to L3; of those 70.4% needed CPAP or invasive ventilation. In the HFNC-availability period, 5.5% were transferred to L3, of those 89.4% received CPAP or invasive ventilation. No serious adverse effects in HFNC group.	Moderate
Kumar 1997	India	Prospective cohort	0-60 months	To compare the efficacy and acceptability of four commonly used oxygen delivery systems	80	Hospital Ward	Step wise approach to O2 administration via head box, facemask, NC, and twin-based pre-nasal catheter	More children achieved paO2 > 90mmHg with head box (69%), vs face mask (57%), vs nasopharyngeal catheter (26 %), twin-holed pre-nasal catheter (25%)	Low
<b>CPAP, including bubble (n=6)</b>									
<i>Pneumonia</i>									
Chisti 2015	Bangladesh	RCT	<59 months	To evaluate whether oxygen therapy delivered by bubble continuous positive airway pressure (CPAP) improved	225	Intensive Care Unit	Bubble CPAP versus high-flow (2L/kg per minute up to max of 12 L/min) versus	Lower rates of death (4% vs. 15%; RR 0.25; 95% CI 0.07-0.89; p=0.022) and treatment failure in bCPAP vs low-flow oxygen group ([RR] 0.27, 99.7% CI 0.7,0.99; p=0.0026). No difference in treatment failure was noted	Some

				outcomes compared with standard low-flow and high-flow oxygen therapies			standard low-flow nasal cannula (2L/min)	between patients in the bubble CPAP and those in the high-flow oxygen group (RR 0.50, 99.7% 0.11,2.29; p=0.175).	
McCollum 2019	Malawi	RCT	1-59 months	To evaluate whether bubble CPAP improves severe pneumonia mortality in children with high-risk conditions	664	Hospital Ward	1:1 to low-flow nasal cannula oxygen or nasal bCPAP	Greater relative risk of hospital death (17% vs 11%; RR 1.52, 95% CI 1.02,2.27; p=0.036) with bCPAP vs low-flow oxygen. The RR of 2-week hospital treatment failure in the treatment group was 1.32 (95% CI 0.96,1.83); p=0.081). There was no significant difference in 30-day post discharge mortality in the two groups.	Some
<b>Acute respiratory distress</b>									
Machen 2015	Malawi	Prospective cohort	8-416 days	To describe the outcomes of infants and young children with respiratory distress when treated with a novel, low-cost, stand-alone bubble Continuous Positive Airway Pressure (bCPAP) system in a resource-limited setting	75	Hospital Ward	Bubble CPAP	All physicians surveyed stated that bubble CPAP was useful and led to a change in clinical practice; 80% of survivors had a lower Respiratory Index of Severity in Children (RISC) score 24 hours after starting bubble CPAP	Moderate
Wilson 2013	Ghana	RCT	3-60 months	To evaluate the effectiveness of immediate versus delayed CPAP in children presenting with acute respiratory distress	70	ED / A&E	Immediate vs delayed CPAP	Mean respiratory rate of children who received immediate CPAP fell by 16 breaths/min (95% CI 10-21) in the first hour compared with no change in children who had CPAP delayed by 1 hour (95% CI 2 to +5) p<0.001	Low
Wilson 2017	Ghana	RCT	1-60 months	To determine if continuous positive airway pressure (CPAP), a form of non-invasive ventilation, decreases all-cause mortality in children with undifferentiated respiratory distress in Ghana	2,200	ED / A&E	Nasal CPAP	No difference in 2-week mortality in unadjusted analysis; 26 (3%) of 1021 patients in the CPAP group, and 44 (4%) of 1160 patients in the control group, had died (relative risk [RR] of mortality 0.67, 95% CI 0.42, 1.08; p=0.11. However, in adjusted analysis, in children younger than 1-year, all-cause mortality was ten (3%) of 374 patients in the CPAP group, and 24 (7%) of 359 patients in the control group (RR 0.40, 0.19-0.82; p=0.01).	Low
<b>Bronchiolitis</b>									
Lal 2018	India	RCT	1-12 months	To evaluate the efficacy of nasal continuous positive airway pressure (nCPAP) in decreasing respiratory distress in bronchiolitis	72	Hospital Ward	Oxygen via bubble CPAP for 60 minutes	Improvement in respiratory rate [8.0 (5.8) vs 5.1 (4.0), P=0.02], Silverman-Anderson score [0.78 (0.87) vs 0.39 (0.73), P=0.029] and in Modified Pediatric Society of New Zealand Severity Score [2.5 (3.01) vs. 1.08 (1.3), P=0.012]	Some

								were significantly different in the CPAP and standard care groups, respectively	
<b>Supportive care (n=5)</b>									
<b>Physiotherapy (n=4)</b>									
<b>Pneumonia</b>									
Abdelbasset 2015	Egypt	RCT	1-59 months	To evaluate the effect of chest physiotherapy on children with pneumonia	50	Hospital Ward	Chest physical therapy x20 minutes TID during admission	Shorter time to clinical resolution (4 vs 7 days, p=0.012) and greater reduction in respiratory rate (40 to 30 bpm vs 39 to 34 bpm, p= 0.001) and arterial oxygen saturation (93% to 98% vs 93% to 95%, p=0.002) chest PT group.	Some
Lukrafka 2012	Brazil	RCT	1-12 years	To evaluate the efficacy of chest physiotherapy as an adjuvant treatment in children hospitalized with acute community acquired pneumonia	79	Hospital Ward	Chest physiotherapy for 10-12 minutes TID during hospital admission	No differences between groups in severity score, respiratory rate, or duration of hospitalization between the control and intervention groups (6 vs 8 days, p=0.11, respectively).	Some
<b>Bronchiolitis</b>									
Bohe 2004	Argentina	RCT	<24 months	To determine if chest physical therapy is useful in the treatment of bronchiolitis and if it decreases the length of hospitalization	32	Hospital Ward	Chest physiotherapy compared to standard nasal aspiration	No significant difference in severity score at admission (5.56 +/- 1.96 vs 5.75 +/- 1.61, p=0.77) or discharge (3.25 +/- 1.27 vs 3.12 +/- 1.15, p=0.76), or in LOS (4.0 +/- 2 vs 3.87 +/- 1.3, p=0.84) between intervention vs control	Some
Gomes 2012	Brazil	RCT	1-24 months	To evaluate the effectiveness of chest physical therapy (CP) in reducing the clinical score in infants with acute viral bronchiolitis (AVB)	30	Hospital Ward and ICU	1) new Chest PT (nCPT) with prolonged slow expiration (PSE) and clearance rhino pharyngeal retrograde (CRR); 2) convention (cCPT) Chest physical therapy with conventional techniques 3) Suction of the upper airways.	Wang respiratory score on admission was reduced in group 1 (7.0 to 4.0; pre/post) and group 2 (7.5 to 5.5) but was unchanged in group 3 (7.5 to 7.0); observed a change 48 hours after hospitalization in group 1 (5.5 to 3.0) and group 2 (4.0 to 2.0) and in 72 hours, there was a change in group 1 (2.0 to 1.0) compared with cCPT	Some
<b>Other (n=1)</b>									
Singh 1990	India	Non-randomized clinical trial	1-36 months	To evaluate effect of steam therapy in acute lower respiratory tract infections	36	ED / A&E	Standard of care, study group also received steam from a steam-kettle in a cloth tent.	No significant difference in duration of respiratory distress in children with pneumonia, though there was some improvement for those with bronchiolitis.	Some
<i>Abbreviations: bCPAP: bubble continuous positive airway pressure; CI: confidence interval; IRR: incidence rate ratio; LOS: length-of-stay</i>									

**Table 3. Summary of Findings – Medications (N=80).**

Study ID	Country	Design	Age	Study Aim	N	Setting	Intervention	Key Findings	RoB
<b>Antibiotics (n=17)</b>									
<b>Severe Pneumonia</b>									
Addo-Yobo 2004	Colombia, Ghana, India, Mexico, Pakistan, South Africa, Vietnam, Zambia	RCT	3-59 months	To do a multicenter equivalency study comparing oral amoxicillin with injectable penicillin in the treatment of WHO-defined severe pneumonia in children	1,702	Hospital Ward	Oral Amoxicillin 45mg/kg per day in 3 doses for 48h	Treatment failure was 19% in each group (161 patients, penicillin; 167 amoxicillin; risk difference ,0-4%; 95% CI, 4.2-3.3) at 48 h. Infancy (age 3-11 months; odds ratio 2.72, 95% CI 1.95 to 3.79), very fast breathing (1.94,1.42 to 2.65), and hypoxia (1.95, 1.34 to 2.82) at baseline predicted treatment failure by multivariate analysis	Some
Agweyu 2015	Kenya	RCT	2-59 months	To compare amoxicillin and penicillin in a population of Kenyan children with pneumonia	527	Hospital Ward	Oral amoxicillin 40-45mg/kg twice daily (vs IV/IM benzylpenicillin 50, IU/kg 4 times daily) for minimum of 48h	Treatment failure was observed in 20 of 260 (7.7%) and 21 of 261 (8.0%) of patients in the amoxicillin and benzyl penicillin arms, respectively (risk difference, 0.3% [95% confidence interval, ,5.0% to 4.3%]). Treatment failure by day 5 post-enrollment was 11.4% and 11.0% and rising to 13.5% and 16.8% by day 14 in the amoxicillin vs benzyl penicillin groups, respectively.	Some
Asghar 2008	Bangladesh, Ecuador, India, Mexico, Pakistan, Yemen, Zambia	RCT	2-59 months	To evaluate injectable ampicillin/gentamicin compared with chloramphenicol to reduce treatment failure in community acquired very severe pediatric pneumonia	958	Hospital Ward	Injection ampicillin/gentamicin 200mg/kg/d x 4 doses q6h; control chloramphenicol 75 mg/kg/k q8h x 3 doses	Treatment failure higher in chloramphenicol vs. amp/gent group (RR 1.43, 95%CI 1.03-1.97) at day 5 and for secondary outcomes at 48 hours (RR 1.6, 95%CI 1.1-2.5), and day 10 (RR 1.37, 95%CI 1.03-1.83) and 21 days (RR1.34, 95%CI 1.02-1.75)	Low
Cetinkaya 2004	Turkey	RCT	2-24 months	To evaluate the effectiveness of two different antibiotic regimens in the empirical treatment of severe childhood pneumonia	97	Hospital Ward	Ceftriaxone 50mg/kg every 12h vs Pen C (25,000U/kg every 4h plus chloramphenicol (15mg/kg every 6h)	There was no significant difference in cure rates between control group and ceftriaxone group (84.7% vs 80.4%, p >0.05). The number of nurse rounds was much more in control group than ceftriaxone group (80 vs 20, p <0.05).	Some

Duke 2002	Papua New Guinea	RCT	1-59 months	To establish whether the combination of benzylpenicillin and gentamicin or chloramphenicol would be better as first-line treatment in children with severe pneumonia in Papua New Guinea.	1,116	Hospital Ward	Benzylpenicillin (50mg/kg, 6 hourly) and Gentamicin (7.5 mg/kg daily) vs Chloramphenicol (25mg/kg 6-hourly), all IM for at least 5 days.	There was no significant difference in mortality (6% vs. 5%; p=0.35), adverse outcomes (26% vs. 22%; p = 0.11) in chloramphenicol versus penicillin/gentamicin groups.	Some
Hazir 2008	Pakistan	RCT	3-59 months	To determine whether home treatment with high-dose oral amoxicillin and inpatient treatment with parenteral ampicillin were equivalent for the treatment of severe pneumonia in children	2,037	Hospital Ward	Oral amoxicillin syrup (80-90 mg/kg per day in two doses) and sent home (ambulatory group), or IV ampicillin (100 mg/kg per day in four doses) for 48 h as an inpatient (hospitalized group)	87 (8.6%) treatment failures in the hospitalized group and 77 (7.5%) in the ambulatory group (risk difference 1.1%; 95% CI , 1.3 to 3.5) by day 6. Five (0.2%) children died within 14 days of enrolment, one in the ambulatory group and four in the hospitalized group	Some
Jeena 2006	South Africa, Zambia	RCT	3-59 months	To determine whether children aged 3-59 months with mild or non-symptomatic human immunodeficiency virus (HIV) infection and WHO-defined severe pneumonia have a higher failure rate than do HIV-uninfected children when treated with the standard WHO treatment of parenteral penicillin or oral amoxicillin.	464	Hospital Ward	Amoxicillin syrup 45 mg/kg/day in 3 doses or parenteral penicillin 200,000 IU/kg/day in 4 dose for 2 days	Twenty (18.9%) HIV-infected children failed by day 2 compared with 37 (10.3%) uninfected children (adjusted odds ratio (OR) 2.07; 95% confidence interval (CI): 1.07,4.00). Thirty-four (32.1%) HIV-infected children failed treatment by day 14 compared with 76 (21.2%) uninfected children (adjusted OR 1.88; 95% CI: 1.11,3.17). Analysis stratified by age showed that the greatest differential in treatment failure at day 2 and day 14 occurred in the children aged 3-5 months	Low
Ribeiro 2011	Brazil	RCT	2-59 months	To compare clinical response to initial empiric treatment with oxacillin plus ceftriaxone and amoxicillin plus clavulanic acid in hospitalized children diagnosed with very severe community-acquired pneumonia (CAP)	104	Hospital Ward	IV oxacillin at 200 mg/kg/day every 6 hours for 10 days and ceftriaxone IV at 100 mg/kg/day every 12 hours for 10 days versus amoxicillin/clavulanic acid IV at 100 mg/kg/day every 8 hours at the beginning of amoxicillin base treatment	Time to improve tachypnea was less among amoxicillin/clavulanic acid versus oxacillin/ceftriaxone (4.8 ± 2.2 versus 5.8 ± 2.4 days respectively; P = 0.028), as was length of hospital stay (11.0 ± 6.2 versus 14.4 ± 4.5 days respectively; P = 0.002).	Low



Shann 1985	Papua New Guinea	RCT	Not specified	To evaluate whether chloramphenicol plus penicillin is any more effective than chloramphenicol alone	748	Hospital Ward	IM Chloramphenicol 25 mg/kg q 6 h until improvement and then the 25 mg/kg of chloramphenicol PO Q6 h versus Benzylpenicillin IM Q6 h 250 000 units 3-9 kg, and 500 000 u to children 10-19 kg.	No difference in mortality rate between groups (17% chloramphenicol/penicillin vs. 13% chloramphenicol alone).	High
<b>Pneumonia</b>									
Brekhna 2003	Pakistan	RCT	3-72 months	To compare amoxicillin, cefuroxime, clarithromycin in CAP in children	124	Hospital Ward	Group 1: Amoxicillin 75mg/kg/day IV TID vs Group 2: Cefuroxime 75mg/kg/day IV TID, Group 3: Clarithromycin 15mg/kg/day IV BID	No difference in clinical response between treatment groups as measured by RR (p= 0.7), temperature (p = 0.5), oxygen requirement (p = 0.10), inability to feed (p = 0.2)	High
Hasali 2005	Malaysia	RCT	2-59 months	To evaluate the effect of antibiotic regimens used in pediatric community-acquired pneumonia (CAP) management and to conduct a cost-effectiveness analysis (CE) between IV ampicillin versus combination therapy of IV ampicillin and IV gentamicin	40	Hospital Ward	IV ampicillin 100 mg/kg/day divided every 6 h and 5 mg/kg of IV gentamicin as a single daily dose compared to IV ampicillin alone	Shorter antibiotic duration (3.80 ± 1.01 vs 4.80 ± 0.41, P<0.05); Days of hospital stay 3.85 ± 1.10 vs 4.80 ± 0.41 (control vs intervention, p <0.05); time to switch to PO therapy (3.80 ± 1.01 vs 4.80 ± 0.41, p <0.05) in those receiving ampicillin alone.	Some
Mulholland 1995	The Gambia	RCT	0-59 months	To evaluate the effect of chloramphenicol vs. trimethoprim-sulfamethoxazole for the treatment of malnourished children with community-acquired pneumonia	111	Hospital Ward	PO chloramphenicol palmitate 25 mg/kg every 8 hours vs tmp/smx PO 20/200 mg <12 month and 60/300 BID >12-month x 7 days	No difference in number of treatment failures between the treatment group and the control group (16 vs 16)	Some
Straus 1998	Pakistan	RCT	2-59 months	To study effectiveness of co-trimoxazole compared with that amoxicillin in pneumonia therapy, and assessed the clinical impact of co-trimoxazole resistance	595	Hospital Ward	Co-trimoxazole BID (20 mg/kg sulfamethoxazole, 4 mg/kg trimethoprim) versus amoxicillin TID (15 mg/kg per dose)	There were 92 (23%) therapy failures in the co-trimoxazole group and 30 (15%) in the amoxycillin group (p = 0.03) , 26 (13%) versus 12 (12%) among children with non-severe pneumonia (p=0.856) and 66 (33%) versus 18 (18%) among those with severe pneumonia (p= 0.009)	Low

<b>Bronchiolitis</b>									
Kabir 2009	Bangladesh	RCT	<24 months	To ascertain the effect of antibiotics in the management of bronchiolitis	295	Hospital Ward	(i) parenteral ampicillin at 50 mg/kg every 6 hours IV n=99 (ii) oral erythromycin at 10 mg/kg every 6 hours considering Mycoplasma pneumoniae n=99 (iii) no antibiotics n=97	No difference in time to clinical sign recovery (cough, difficulty breathing, wheeze, chest indrawing, tachypnea, tachycardia, rhonchi, crepitation) among three intervention groups ( $p>0.23$ , $p<0.62$ , $p = 0.54$ , $p <0.27$ , $p = 0.75$ , $p = 0.76$ , $p = 0.81$ , $p >0.98$ , respectively). Children in no antibiotic group had shorter LOS ( $3.7 \pm 1.5$ ) than parenteral antibiotic group ( $4.3 \pm 1.9$ ) or oral antibiotic group ( $4.4 \pm 1.9$ ) ( $p<0.001$ )	Some
Pinto 2012	Brazil	RCT	<12 months	To evaluate if azithromycin reduces the length of hospitalization and oxygen requirement in infants with acute viral bronchiolitis (AB).	184	ED / A&E	Azithromycin 10 mg/kg/d or placebo, administered orally, for 7 days.	The use of azithromycin did not reduce the median number of days of either hospitalization ( $p= 0.28$ ) or oxygen requirement ( $p=0.47$ )	Low
<b>SARI</b>									
Gamiño-Arroyo 2019	Mexico	RCT	>12 months	To evaluate the effectiveness of nitazoxanide (NTZ) for acute respiratory viral illness	257	Hospital Ward	NTZ 600mg for > 12yo, 200mg for 4-11yo, 100mg for 1-3yo; twice daily for 5 days	No difference in hospital LOS (6.5 days in the NTZ group vs 7.0 in the placebo group; $p = 0.56$ ). No difference in hospital LOS similar in children ( $p = 0.29$ ) and adults ( $p = 0.62$ ).	Low
<b>Nebulized treatment (n=17)</b>									
<b>Bronchiolitis</b>									
Adhikari 2016	Nepal	Prospective cohort	2-24 months	To compare initial response of nebulized adrenaline and salbutamol for infants and young children admitted with bronchiolitis	80	Hospital Ward	Adrenaline 0.1 ml/kg 1:1000 nebulization q6h versus Salbutamol nebulization 0.15 mg/kg q6h	No difference in mean RDAI scores over 48 hours to 4.15 (CI 3.57, 4.73) and 4.13 (CI- 3.69, 4.56), hospital LOS (5.32 days vs. 5.68 days) in adrenaline and salbutamol group respectively. Patients nebulized with adrenaline required oxygen for 33.30 hours compared with 36.45 hours in salbutamol.	Serious
Ejaz 2015	Pakistan	RCT	1-24 months	To evaluate the effect of nebulized 3% hypertonic saline or NS on patients with acute bronchiolitis	80	ED / A&E	Nebulized 3% hypertonic saline (3 cc) vs Nebulized NS (3cc)	The HS group had a significantly greater reduction in respiratory score than NS ( $3.23\pm 1.17$ vs $2.05 \pm 0.50$ , $p <0.001$ )	High
Farrah 2014	Pakistan	RCT	2-24 months	To evaluate the effect of nebulized N-acetylcysteine in treatment of bronchiolitis	100	Hospital Ward	Group 1 20mg NAC in 3ml saline nebulization; group-2 received inhalation of 2.5 mg salbutamol in 3 ml saline nebulization. TID x 5 days.	Clinical severity score improved on day 3 ( $2.90 \pm 1.48$ vs $0.88 \pm 1.08$ ) and day 5 ( $3.30 \pm 1.77$ and $1.90 \pm 1.32$ ) in NAC group vs control. Shorter LOS in NAC group $4.36 \pm 1.66$ days vs control $4.98 \pm 2.6$ days ( $p = 0.108$ )	High
Tinsa 2009	Tunisia	RCT	<12 months	To evaluate the efficacy of nebulized terbutaline in bronchiolitis	35	Hospital Ward	Nebulized Terbutaline 0.15mg/kg, repeated at 30 minutes, then every	No significant differences at baseline, 30 minutes, 60 minutes 120 minutes in RDAI	Some

							4 hours for the study period versus nebulized saline	score, O2 sat, RR, HR, or duration of hospitalization for terbutaline versus saline.	
Gadomski 1994	Egypt	RCT	<18 months	To determine the efficacy of albuterol in reducing respiratory distress in infants with bronchiolitis and assess which route of delivery is more effective (nebulization vs oral)	169	Other: Outpatient and casualty department	Albuterol neb 0.15mg/kg per dose 30 minutes apart x 2 doses; oral albuterol 0.15mg/kg per dose x 1 dose; oral placebo; nebulized saline	No difference among four groups in heart rate, respiratory rate, or SpO2 (except for increase in HR in nebulized albuterol group at 60 minutes p = 0.058). However, in recurrent wheezing group nebulized albuterol improved clinical score (8-point decrease, p=0.0003)	Some
Jawaria 2015	Pakistan	RCT	<24 months	To compare the efficacy of normal saline and inhaled beta-agonist in the treatment of bronchiolitis	72	Hospital Ward	Salbutamol nebulization 0.2mg/kg in 2cc NS q4h (group A) vs NS nebulization q4h (group B)	58.33% in Group-A (intervention) and 25% in Group-B were "treated effectively" as measured by reduction in clinical bronchiolitis severity score (p=0.008).	High
Khashabi 2005	Iran	RCT	2-24 months	To compare the efficacy of nebulized epinephrine with salbutamol on infants with severe bronchiolitis	72	ED / A&E	Epinephrine 0.1ml/kg; salbutamol 0.15 mg/kg; normal saline (placebo). Drug mixed with normal saline for total volume 5mL and nebulized x 3 doses each 20 minutes apart	Pre- and post-treatment mean oxygen saturation, clinical score, and respiratory rate significantly different (p <0.00) between the three groups. Mean SaO2 increased from 86.4 to 91.9 in epinephrine and 84.3 to 90.5 in salbutamol groups (p = 0.00 pre- vs. post-intervention), however no significant difference in placebo group for SaO2 86.3 to 88.8 (p=0.1). Pre- and post-intervention clinical score different in all study groups (p = 0.035).	Low
Kumar A 2019	India	RCT	2-24 months	To compare 3% versus 0.9% saline nebulization in children with bronchiolitis	150	Hospital Ward	3 mL Nebulized Saline 3%	At 24 hours, lower mean clinical severity score for control group was 2.49±1.03 and treatment group was 2.16±0.49 (P=0.013). Improvement in O2 saturation in the treatment group was better in the first 24 hours (55% vs 28%, p <0.05). The duration of hospital stay was shorter in treatment group (2.35 days vs 4.04 days, p <0.001).	Some
Modaressi 2012	Iran	RCT	1-24 months	To determine the efficacy of epinephrine compared to salbutamol in treatment of bronchiolitis	40	Hospital Ward	Epinephrine 0.1 mg/kg vs salbutamol 0.15 mg/kg. Three doses given at 20-minute intervals	Mean hospital duration was 3.3 +/- 1.1 vs 3 +/- 0.9 salbutamol vs epinephrine (p=0.03). Significant difference in RDAI between the groups (p = 0.02). No difference in SpO2, heart rate, respiratory rate	Some
Ojha 2014	Nepal	RCT	1.5-24 months	To evaluate the clinical profile and the effect of use of hypertonic (3%) saline vs NS	72	ED / A&E	Nebulized 3% Saline vs NS every 8 hours each day until discharge	No difference between intervention and control. Mean (±SD) for duration of hospital stay was 44.82 (±23.15) and 43.60 (±28.25) for 3% and 0.9% group respectively (p = 0.86). Likewise, mean (SD) duration of oxygen supplementation was 32.50 (±20.44) and 34.50 (±26.03) for 3% and 0.9% group respectively (p = 0.85). Moreover, time required for normalization of clinical score was 36.79 (±19.53) and	Low

								38.34 ( $\pm$ 26.67) for 3% and 0.9% group respectively ( $p = 0.80$ ).	
Pukai 2020	Papua New Guinea	RCT	<24 months	To determine if nebulized normal saline vs standard care was beneficial in bronchiolitis	199	ED / A&E	1-3 doses of nebulized saline 2 ml per dose over the first 3 hours in addition to standard care or standard care	Greater reduction in mean respiratory distress score (RDS) at 4 hours by 3.41 (95% CI 3.0-3.8) versus 1.96 (95% CI 1.5-2.4, $p < 0.0001$ ), increase in SpO <sub>2</sub> at 4 hours (7% vs 4%; $p < 0.001$ ), and ability to be discharged from ED (58% vs 28.2%; $p < 0.001$ ) in NS vs standard of care group.	Low
Ray 2002	India	RCT	2-24 months	To assess the efficacy of bronchodilators in wheeze associated respiratory tract infection (WRTI); and (ii) To compare L-adrenaline with salbutamol in WRTI	91	Hospital Ward	L-adrenaline (0.1ml/kg/dose in 1in 10,000 solution) salbutamol (0.1mg/kg/dose) nebulized each at 20 minutes intervals 3 total doses.	Lower mean respiratory rate, RDAI score, clinical score in adrenaline versus salbutamol group, after three doses of nebulization. More patients with improved respiratory distress in adrenaline vs salbutamol (28/44 in Group A vs 12/46in Group B, $p < 0.001$ ). Fewer patients in adrenaline vs salbutamol (6/45 vs 14/46 requiring admission, $p = 0.02$ )	Some
Shankar 2019	India	Retrospective	6-24 months	To determine if there is significantly shorter duration of stay between children who were given hypertonic saline neb and adrenaline neb.	90	Hospital Ward	Adrenaline nebulization vs hypertonic saline nebulization	Mean duration of stay for children treated with adrenaline nebulization was 5.3 days and those given hypertonic saline was 4.8 days ( $p = 0.29$ ). No significant difference.	Moderate
Sharma 2013	India	RCT	1-24 months	To compare the length of hospital, stay and improvement in clinical severity scores among children with bronchiolitis nebulized with 3 % hypertonic saline or 0.9% saline	248	Hospital Ward	4 mL 3% hypertonic saline nebulized q4h until discharge	Clinical severity scores monitored afterwards q12h till discharge did not show statistically significant differences in 3% and 0.9% saline groups. Mean length of hospital stays (time to reach predefined clinical severity score<3) was 63.93 $\pm$ 22.43 h in 3% saline group and 63.51 $\pm$ 21.27 h in 0.9% saline group ( $p = 0.878$ ).	Low
Soleimani 2020	Iran	RCT	1-24 months	To investigate the effects of saline usage with different concentrations and salbutamol on the treatment	180	Hospital Ward	Group 1: normal saline 0.9% and 0.15 mg/kg salbutamol nebulizer  Group 2: 3% and 0.15 mg/kg salbutamol nebulizer  Group 3: Hypertonic saline 5% and 0.15 mg/kg salbutamol nebulizer	Shorter hospital LOS in Group 2 (4.63 + 1.34, 3.41 + 1.07, and 4.61 + 0.72 days in Group 1, Group 2, Group 3; $p < 0.001$ ). Decrease in clinical bronchiolitis severity score in Group 1 and Group 3 at 20, 40 and 60 minutes after treatment in both groups ( $P < 0.001$ ) and in Group 2 at 20 and 40 minutes after treatment.	Some
Tinsa 2014	Tunisia	RCT	<12 months	to evaluate the efficacy of nebulized NS vs 5% hypertonic saline alone	94	ED / A&E	NS vs 5% HS vs 5% NS with 0.1% epi nebulized at admission	No significant difference between the 3 groups in severity score, oxygen saturation, clinical signs, or length of stay	Some

				or mixed with epi in bronchiolitis			and every 4 hours throughout hospitalization		
<b>Croup</b>									
Eghbali 2016	Iran	RCT	6 months -6 years	To compare the effect of L-epinephrine plus dexamethasone vs. dexamethasone for treatment of croup in children.	174	Hospital Ward	Single dose L-epinephrine (0.5 mg/kg) with 3ml saline nebulized + Dexamethasone 0.6mg/kg IM vs Dexamethasone alone	Lower mean of Westley clinical croup scores in L-epinephrine vs control group (p <0.009) at 30, 60, 90 min but not 120 minutes	Some
<b>Nutrients and Minerals (n=17)</b>									
<b>Vitamin A</b>									
<b>ALRTI / Pneumonia</b>									
Donnen 1998	DRC	RCT	0-72 months	To investigate the effect of 1) single high dose vitamin A; 2) daily, low doses of vitamin A; or 3) placebo on ALRTI and diarrhea in hospitalized preschool-age children	900	Hospital Ward	200 000 IU vitamin A (100 000 IU if aged < 12 mo) PO on the day of admission vs 5000 IU vitamin A until discharge.	Mortality rates were not significantly different among the 3 groups. Low-dose vitamin A showed no significant effect on the duration of moderate or severe diarrhea or on the duration and incidence of ALRTIs and all-cause fevers.	Some
Julien 1999	Mozambique	RCT	6-72 months	To evaluate the effect of single high-dose vitamin A supplementation immediately upon admission on recovery in children hospitalized with ALRTI	164	Hospital Ward	200,000 IU vitamin A immediately upon admission (100,000 IU if <1 year)	Median hospital stay 3 in vit A group vs 4 in placebo. Day 5 discharge rate was 99.4% in vit A group vs 73.9% in placebo (p=0.023). No differences between groups at 6-week follow up	Some
Kjollhede 1995	Guatemala	RCT	3-48 months	To test the efficacy of a single high dose of vitamin A as adjuvant treatment for radiographically confirmed cases of ALRTI	263	ED / A&E	200,000 IU Vitamin A (100,000 IU if < 1 year) PO	No difference between groups in the rate of normalization in respiratory rate, oxygen saturation, temperature, or clinical score (p-values not presented). Duration of hospitalization was not different by treatment group. No difference in adverse outcomes (mechanical ventilation, prolonged hospitalization, readmission and death).	Low
Fawzi 1998	Tanzania	RCT	6-60 months	To examine whether large doses of vitamin A given to Tanzanian children hospitalized with non-measles pneumonia would reduce the severity of respiratory disease	687	Hospital Ward	200,000 IU Vitamin A daily x 2 days	No difference in mortality (relative mortality 1.63 95% CI 0.67-0.97; p=0.28) vitamin A vs. placebo. No difference in length of stay (both groups 4.2 days) or time with symptoms.	Low

Hussey 1990	South Africa	RCT	<13 years	To evaluate the effect of Vitamin A on morbidity and mortality in children with severe measles	189	Hospital Ward	40,000 IU Vitamin A PO (1/2 dose on day of admission and 1/2 dose the next day)	Faster recovery in vitamin A vs control group from pneumonia (mean 6.3 vs 12.4 days; $p<0.001$ ) and diarrhea (mean 5.6 vs 8.5 days; $p<0.001$ ); less croup (13 vs 27 cases; $p=0.03$ ); shorter length of hospitalization (mean 10.6 vs 14.8 days; $p=0.01$ ). Of 12 children who died 10 were in placebo group ( $p=0.05$ ) with risk of death lower in Vit A vs control group (RR 0.51, 95%CI 0.35-0.74)	Low
Nacul 1997	Brazil	RCT	6-59 months	To evaluate the impact on clinical recovery and severity of the addition of large doses of vitamin A to the standard treatment for childhood pneumonia.	478	Other: Hospital or outpatient	Capsules 100 000 IU of vitamin A and 20 IU of vitamin E in oil. Infants: 1 capsule on admission and next day. 1-4 years: 2 capsules admission and next day	Similar overall duration of pneumonia (median 7.6 days Vit A vs 7.5 days placebo) and incidence of adverse outcomes. Children who received vitamin A, however, were less likely to have fever by day 3 (16% vs 26.4%, $P = 0.008$ ) and were 29% less likely to fail to respond to the first line antibiotic ( $P = 0.054$ ).	Some
Rodriguez 2005	Ecuador	RCT	2-59 months	To evaluate the effect of a moderate dose of vitamin A as an adjunct to standard antimicrobial treatment on the duration of respiratory signs in children with pneumonia	287	Hospital Ward	PO vit A 50,000 to children aged 2-12, and 100000 IU >12-59 months	No difference in the two groups in duration of pneumonia symptoms (tachypnea, fever, hypoxemia).	Some
Si 1997	Vietnam	RCT	1-59 months	To evaluate the effect of high dose vitamin A on morbidity, and if possible, mortality and moderate in children with severe pneumonia in hospitalized Vietnamese children	592	Hospital Ward	Vitamin A 200 000 IU/mL vs placebo A. For children < 1 y the dosage was 0.5ml day of inclusion and the day after. Children aged 1-4y received two doses of 1.0ml. The children allocated to the vitamin A group received in total 200 000 IU and 400 000 IU of retinol, respectively	No differences were found regarding mean time for normalization of fever, respiratory rate and time of hospitalization. However, with stratification for age, sex, nutrition status, moderately malnourished vitamin A-supplemented children to have a shorter time of hospitalization ( $p = 0.04$ ), due to an effect in females aged > 12 months ( $p = 0.02$ ) and females with very severe pneumonia ( $p = 0.048$ ).	Some
Stephensen 1998	Peru	RCT	3 months -10 years	To test the hypothesis that high-dose vitamin A supplements will enhance recovery of children hospitalized for the treatment of community-acquired pneumonia.	95	Hospital Ward	Children <1 year of age received 100 000 IU vitamin A on admission to the hospital and an additional 50 000 IU the next day. Children >1 year of age received 200 000 IU on admission and 100 000 IU the next day	No difference in hospital LOS among two groups. Children receiving vitamin A had lower blood oxygen saturation (the mean difference on day 3 in hospital was 1.1%), higher prevalence rates of retractions (37% in the vitamin A group vs 15% in the placebo group on day 3), auscultatory evidence of consolidation (28% in the vitamin A group vs 17% in the placebo group on day 3) and were more likely to require supplemental oxygen (21% in the vitamin A group vs 8% in the placebo	Low



								group on day 3) than children in the placebo group.	
<b>Vitamin C and E</b>									
Mahalanabis 2006	India	RCT	Not specified	To evaluate Vitamin E and C as adjunct therapy of pneumonia in children with severe ALRTI	85	Hospital Ward	Vitamin E and vitamin C (each 200 mg twice daily for 6 days)	No benefit for intervention group on four clinical outcomes measured (Recovery rate ratios (95% CI) 0.89 (0.64–1.25), 1.01 (0.72–1.41), 0.86 (0.57– 1.29), and 1.12 (0.77–1.64) for very ill status, feeding difficulty, fever, and tachypnea, respectively).	Some
<b>Vitamin D</b>									
Somnath 2017	India	RCT	2-60 months	To study the effect of single oral dose vitamin D3 in decreasing the duration of hospital stay in children hospitalized with ALRI.	154	ED / A&E	Single dose of 100,000 IU of vitamin D3 PO on day one of admission	No difference in median hospital LOS, mortality, PICU admission, complications.	Some
Choudhary 2012	India	RCT	2-59 months	To determine the role of oral vitamin D supplementation for resolution of severe pneumonia in under-five children	200	ED / A&E	Vitamin D 1000 IU <1 year old; 2000 IU children 1-5 years of age, PO within four hours of admission, then once daily x 4 days versus placebo.	No difference in duration of pneumonia, hospital LOS between treatment groups.	Low
Gupta 2016	India	RCT	2-59 months	To evaluate the efficacy of single oral high dose of Vitamin D3 for treatment of pneumonia in under-five children	324	Hospital Ward	Single dose of 100,000 IU Vitamin D x1 PO	No difference in complete recovery from pneumonia, hospital LOS, and fever clearance time between treatment groups.	Low
Rajshekhar 2016	India	RCT	2-59 months	To evaluate the efficacy of vitamin D supplementation in addition to routine treatment of severe pneumonia in children less than 5 years of age	95	Other: both ward and PICU	Vitamin D 1000 IU for children < 1 year and 2000 IU for >1 year versus placebo, within 4 hours after admission, then once daily x 4 days	No significant difference in time to resolution of pneumonia between the two groups (20.8% vs 62.5% resolved in <24 hours, 62.5% vs. 58.5% in 24-48 hours, and 62.5% vs 31.3% in >48 hours; p=0.14).	High
Dhungel 2015	Pakistan	RCT	2-60 months	To see the efficacy of vitamin D in children with vitamin D deficiency with pneumonia	191	Hospital Ward	IM vitamin D 100,000 units within the first 24 hours of admission vs no treatment	No difference in hospital LOS between groups (5.7 days vitamin D vs. 6.1 days placebo, p=0.28).	High
Manaseki-Holland 2010	Afghanistan	RCT	1 week-3 years	To determine whether (i) supplementation of oral 100 000 IU of vitamin D3 on reducing duration of illness in children with pneumonia	453	Other: in hospital or outpatient	100,000 IU cholecalciferol in 1 mL olive oil x1 dose PO	No difference in the mean number of days to recovery between the vitamin D3 (4.74 days; SD 2.22) and placebo arms (4.98 days; SD 2.89; P = 0.17).	Low

<b>Zinc</b>									
<b>Bronchiolitis</b>									
Ahadi 2020	Iran	RCT	2-23 months	To compare the effect of zinc gluconate and placebo in the treatment of tachypnea, dyspnea and fever in children aged 2 to 23 months with acute bronchiolitis	100	ED / A&E	1% zinc gluconate PO (1 cc/kg in infants under 1 year and 10cc in infants over one year)	Shorter hospital LOS (4.14±1.21 versus 4.64±1.2 days; p=0.016) in zinc vs placebo group. Less wheezing and rhinorrhea in treatment group at 72 hours (16% vs 36%, p=0.023, 0 vs 12%, p=0.027). No difference between the groups in resolution of fever, tachypnea, nasal flaring, retractions, or cyanosis, at 24 hours or 72 hours.	High
Farhad 2011	Iran	RCT	2-23 months	To evaluate the effect of zinc sulfate in improving the clinical manifestations of acute bronchiolitis in children younger than 2 years	50	Hospital Ward	1ml/kg 1% zinc sulfate (<1 year) PO or 20mg elemental zinc if >1yo	At 24 hours more patients had resolution of tachypnea, retractions, wheezing, cyanosis in control group compared to treatment (p=0.04) otherwise no difference in clinical signs between groups	High
<b>Pneumonia</b>									
Bose 2006	India	RCT	2-23 months	To evaluate the effect of adjuvant zinc therapy on recovery from severe pneumonia by hospitalized children receiving standard antibiotic therapy	299	Hospital Ward	20mg zinc sulfate tablet at enrollment and duration of hospitalization	No clinical or statistically significant differences in the duration of tachypnea, hypoxia, chest indrawing, inability to feed, lethargy, severe illness, or hospitalization. No significant difference in time to recovery (RR 0.93, 95%CI 0.72-1.21, p=0.589), hospital LOS (RR 0.93, 95%CI 0.74, 1.17, p=0.550). No significant differences in symptom resolution.	Low
Brooks 2004	Bangladesh	RCT	2-23 months	To evaluate the effect of zinc on duration of severe pneumonia in children	270	Hospital Ward	20mg Zinc PO per day until hospital discharge, first dose within 1 hour of antibiotics	Shorter duration to resolution 72 vs 96 hours, zinc vs control (HR 0.7, 95%CI 0.51-0.98) and hospital LOS (112 hours both, HR 0.75, 95%CI 0.57-0.99). No differences in resolution of indrawing, hypoxia.	Low
Coles 2007	India	RCT	2-23 months	To explore the effect of etiology on the treatment effect of zinc in young children hospitalized for severe pneumonia	295	Hospital Ward	Zinc: 10mg orally twice a day during hospitalization	Greater median hospital LOS found in Zinc group (87.3h vs 68.5h, p=0.025)	High
Howie 2018	The Gambia	RCT	2-59 months	To assess the benefit of adjunct zinc therapy for children with severe pneumonia	604	Hospital Ward	Oral fixed doses of 10 mg elemental zinc daily for infants and 20 mg daily for children x 7 days	No difference in time to resolution of respiratory symptoms (42.3 vs 30.9 hours respectively; P=0.242) or treatment failure between placebo and zinc arms both on day 5 (14.0% vs 14.1%) and day 10 (5.2% vs 5.9%). Time to recovery from lower chest wall indrawing and sternal retraction was longer in the placebo compared to zinc arm (24.4 vs 23.0 hours; P=0.011 and 18.7 vs 11.0 hours; P=0.006 respectively).	Low

Fataki 2014	Tanzania	RCT	6-36 months	To evaluate the effect of Zinc supplementation for pediatric pneumonia	95	Hospital Ward	12.5mg Zinc sulfate monohydrate in water twice daily until hospital discharge	No difference in hospital LOS (IRR: 0.69; 95% CI 0.45-1.06; p=0.09) or proportion of children who were hospitalized for <3 days (RR: 0.85; 95% CI: 0.57-1.25; p=0.40) or <5 days (RR: 1.01; 95% CI: 0.83-1.23; p=0.92).	Low
Heydarian 2020	Iran	RCT	2-59 months	To evaluate the effect of prescribing zinc sulfate on improving the clinical symptoms of pneumonia in 2-59-month-old children	108	Hospital Ward	oral zinc sulfate 10 mg (1 ml/ kg in children younger than one year, and 20 mg/kg for children above one year every 12 hours.	No difference in hospital LOS between groups (5.7 vs. 5.11 days; p=0.174). Shorter duration of fever between the intervention and control groups 24 and 36 hours after hospitalization (p=0.014, p=0.02) but not at 12 and 48 hours after. Improved tachypnea in the intervention group at 36 hours post-hospitalization (p=0.02) but not during hospitalization or 12, 24, or 48 hours after.	Some
Laghari 2019	Pakistan	RCT	28 days-5 months	To evaluate the efficacy of zinc supplementation in alleviating symptoms and shortening of hospital stay in children with pneumonia	100	Hospital Ward	Oral 20 mg/day zinc supplements vs placebo	No difference in clinical signs between the two groups. Slightly shorter hospital stays in the zinc supplemented group (p=.01)	Some
Mahalanabis 2002	India	RCT	9 months -15 years	To evaluate the effect of zinc supplementation on episodes of illness in children with measles accompanied by pneumonia.	85	Hospital Ward	20mg zinc acetate BID x6 days	No difference in duration until resolution of fever [HR 1.08 (0.67, 1.74)] tachypnea [HR1.26 (0.78, 2.05)], return of appetite [HR0.82 (0.47, 1.44)], or improved or cured status [HR 1.07 (0.64, 1.78)].	Some
Qasemzadeh 2014	Iran	RCT	3-60 months	To investigate the effects of short courses of zinc administration on recovery from this disease in hospitalized children.	120	ED / A&E	Zinc every 12 hours until discharge	Decrease in duration of clinical symptoms (50% vs. 41.7% <2 days symptoms; P=0.044) and hospital LOS (20% vs. 40% LOS > 5 days; P=0.004) in zinc versus control group.	Some
Rerksuppaphol 2020	Thailand	RCT	2-60 months	To assess the efficacy of zinc supplementation on the treatment outcomes of pneumonia.	91	Hospital Ward	15 mg elemental zinc twice daily dissolved in 30 ml distilled water, until their discharge from the hospital, or the completion of 7 days.	Shorter hospital LOS (96 vs 144 hours; p=0.008), fever resolution (24 vs 42 hours; p=0.002) and normalization of oxygenation (28 vs 48 hours; p=0.014) in zinc group.	Low
Sempértegui 2014	Ecuador	RCT	2-59 months	To evaluate the effect of zinc given with standard anti-microbial treatment on the duration of respiratory signs in children with severe pneumonia	450	ED / A&E	10 mg elemental zinc (zinc sulfate) in 5 mL syrup BID	No difference in time to resolution of respiratory signs or prevalence of treatment failure (placebo compared with zinc: 34.4% compared with 34.5%; OR: 1.00; 95% CI: 0.68, 1.5)	Low
Shah 2012	Nepal	RCT	2-60 months	To evaluate the efficacy of zinc supplementation	122	Hospital Ward	20 mg zinc sulfate PO or placebo by mouth at	No difference in hospital LOS (p=0.193), severe pneumonia (p=0.219), pneumonia	Some

				in treatment of severe pneumonia in hospitalized children.			enrollment; from day 2, 10 mg zinc twice a day for 7 days.	(p=0.943), no PO intake (p=0.771), IV fluid use (p=0.258), oxygen use (p=0.684) between groups.	
Srinivasan 2012	Uganda	RCT	6-59 months	To determine effect of zinc as adjunct therapy on time to normalization of respiratory rate, temperature and oxygen saturation, and case fatality of severe childhood pneumonia	352	Hospital Ward	zinc (20 mg for children, >12 months, and 10 mg for those < 12 months) or a placebo once daily for seven days, in addition to standard antibiotics	Decreased case fatality among group treated with zinc (4.0% in the zinc and 11.9% in the placebo group with Relative Risk 0.33 (95% CI of 0.15 to 0.76). Excess risk was greater among HIV+ than HIV- children (ARR: 26 (95% CI: 9, 42) per 100 versus 2 (95% CI: -4, 7) per 100). No effect on time to normalization of the respiratory rate, temperature, and oxygen saturation.	Some
Wadhwa 2013	India	RCT	2-24 months	We evaluated the role of zinc as an adjunct to antibiotics in the treatment of children hospitalized for severe or very severe pneumonia	550	Hospital Ward	10 mg zinc PO on admission and every 12 h until recovery or the completion of 14 days.	No difference in time to recovery from severe or very severe pneumonia (HR: 0.98; 95% CI: 0.82, 1.17). In the stratified analysis, zinc was shown to be efficacious in reducing the time to recovery in children with very severe pneumonia (HR: 1.52; 95% CI: 1.03, 2.23).	Low
Valentiner-Branth 2010	Nepal	RCT	2-35 months	To measure the effect of zinc supplementation in children with pneumonia in a population in which zinc deficiency is common.	2,628	Other: Study clinic	10mg zinc sulfate PO or placebo; 10 mg for children aged 2-11 mo. and 20 mg for children aged >12 mo then daily x 14 days.	No difference in time to recovery between zinc and placebo groups for non-severe (median: 2 d; hazard ratio: 1.0; 95% CI 0.96-1.1) or severe (median: 4 d; hazard ratio: 1.1; 95% CI 0.79-1.5) pneumonia	Low
<b>Steroids (n=10)</b>									
<b>Bronchiolitis</b>									
Ahmad 2011	Pakistan	RCT	3-24 months	To determine the efficacy of steroids in bronchiolitis	90	Hospital Ward	Group 1 IV hydrocortisone 5mg/kg/dose q6h; Group 2 nebulized Beclomethasone 400-1000 ug q8h; Group 3 no steroids	No difference between groups in LOS (p=0.259), wheeze-free (p=0.40) or mean difference in RDAI (p=0.056)	Some
Mesquita 2009	Paraguay	RCT	2-24 months	To compare the efficacy of a single dose of oral dexamethasone in infants with moderate to severe bronchiolitis presenting to an ED	65	ED / A&E	Single dose oral dexamethasone 0.5mg/kg PO versus placebo in addition to standard of care (nebulized adrenaline)	No differences in RDAI (p=1.0), heart rate (p=0.4) and respiratory rate (p=0.3) and SpO2 (p=1.0) between groups after the 1st and 4th hours. No difference in hospitalization rate between groups (21 % vs. 25 %, p = 0.9, respectively)	Some
Qureshi 2015	Pakistan	RCT	2-24 months	To compare the mean duration of bronchiolitis in children receiving standard treatment with and without IV steroids	140	Hospital Ward	IV hydrocortisone 10mg/kg/day TID x 7 days	No difference between treatment and placebo groups for hospital LOS (5 vs 4.87 days, p=0.604), duration of wheezing (4.07 vs 4.26 days, p=0.535) or tachypnea (4.7 vs 4.5 days, p=0.471).	Low
Teeratakulpisarn 2007	Thailand	RCT	0.5-24 months	To examine the efficacy of a single intramuscular	174	ED / A&E	Dexamethasone (a single intramuscular	Decreased time to resolution of respiratory distress (HR 1.56; 95% CI, 1.14, 2.13;	Low


				injection of dexamethasone in children hospitalized with acute bronchiolitis and followed up for 1 month after discharge			injection of 0.6 mg/kg or placebo solution (an equivalent volume of saline) in a container of identical appearance	P<0.005), mean duration of symptoms of 11.8 hours (95% CI, 3.9,19.7; P<0.004), mean duration of oxygen therapy of 14.9 hours (95% CI, 5.3,24.4; P<0.003), and mean length of hospital stay of 13.4 hours (95%CI, 2.6,24.2; P<0.02) in dexamethasone group.	
Virk 2014	Pakistan	RCT	3-24 months	To compare the efficacy of prednisolone as an adjunct to conventional treatment or conventional treatment alone in patients of bronchiolitis	80	Hospital Ward	Oral prednisolone 2mg/kg/day in 3 divided doses	Decreased rhonchi on the third day of admission 67.5% vs 22.5%, p<0.0001), and shorter hospital LOS (4.72±1.17 days vs 5.72±1.5 days; p = 0.0014) in prednisolone group.	High
Zhang 2003	Brazil	RCT	<12 months	To assess short-term (and long-term) effect of prednisolone in hospitalized infants with bronchiolitis	52	Hospital Ward	1 mg/kg/day prednisolone x5 days	No difference in hospital LOS (6.0 vs 5.0 days, P = 0.7), duration of oxygen therapy (24.0 vs 24.0 h, P = 0.4) and time to clinical resolution (4.0 vs 4.0 days, P = 0.8)	Some
<b>Croup</b>									
Sumboonnanda 1997	Thailand	RCT	2-37 months	To determine the beneficial effect of dexamethasone in children with moderate to severe infectious croup	32	Hospital Ward	0.5 mg/kg/d IM/IV dexamethasone x3 days	The dexamethasone group had significantly lower croup scores at 48 hour (p < 0.05), shorter hospital course (p < 0.005) and lower incidence of endotracheal intubation (p < 0.05) than the control group	Some
<b>PJP Pneumonia</b>									
Green 2008	South Africa	RCT	<18 months	To determine the efficacy and safety of adjunctive corticosteroid therapy in clinical Pneumocystis jiroveci pneumonia (PJP) in infants exposed to HIV infection	100	Hospital Ward	PO prednisone 2 mg/kg/day for 7 days.	43% better chance of survival in steroid vs. placebo group (hazard ratio (HR) 0.57, 95% confidence interval (CI) 0.30 - 1.07, p=0.08). No significant differences found with other parameters (oxygen requirement, time to recovery).	Low
Newberry 2017	Malawi	RCT	2-6 months	To determine whether early administration of adjuvant corticosteroids in addition to standard treatment reduces mortality in infants with vertically acquired HIV and clinically diagnosed PJP when co-infection with cytomegalovirus and other pathogens cannot be excluded	78	ED / A&E	Steroid regimen consisted of once daily oral prednisolone, 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5 mg/kg for 7 days for a total of 21 days	Risk ratio of in-hospital mortality in the steroid group compared with the standard treatment plus placebo group was 0.53 [95% CI 0.29,0.97, p = 0.038]. The risk ratio of mortality at 6 months was 0.63 (95% CI 0.41, 0.95, p = 0.029).	Low
<b>Other medications (n=4)</b>									
<b>Bronchiolitis</b>									

Shang 2017	China	RCT	3-24 months	To evaluate the efficacy and safety of Laggera pterodonta in hospitalized children aged 3-24 months with acute bronchiolitis	133	Hospital Ward	Laggera pterodonta mixture as tincture/syrup, q8h x 5 days	More children fulfilled the discharge criteria at 96 h and 120 h in the Laggera pterodontamixture group compared to the control group (97% vs 75.8%; P<0.001 and 98.5% vs 89.4%; P=0.03), although no difference at 72 h. Lower respiratory rate and oxygen saturation levels (p<0.001) in treatment group.	Some
<b>Influenza</b>									
Dawood 2016	El Salvador, Panama	RCT	0-9 years		688	Hospital Ward	Oseltamivir: 0-11 mo, 3mg/kg/dose; >=12m: 30mg/dose if <=15kg, 45mg if 15-23kg; 60mg if 23-40kg, 75mg if >40kg. Every 12h for 10 doses.	No difference in median hospital LOS (3 days, IQR 2-4 vs. 5 days, IQR 3-7, p=0.22) or work of breathing (36 h, IQR 24-72 vs. 96 h, IQR 13-108, p=0.14) between oseltamivir versus placebo.	Some
<b>Pneumonia</b>									
Adinatha 2020	Indonesia	RCT	2-59 months	To evaluate the probiotic effectiveness as adjuvant therapy in childhood pneumonia compared to placebo	54	Hospital Ward	Probiotics (L. acidophilus, B. longum, Streptococcus thermophilus each 1x10 <sup>7</sup> cfu/gr) granules 2 times a day for 5 days versus placebo	No difference on hospital LOS, duration of fever, retractions between two groups (p>0.05). However, decreased rates duration (p=0.037).	High
BecinaPaoloGene 2014	Philippines	RCT	2 months -4 years	To determine the efficacy of probiotics as adjunct therapy for pediatric community-acquired pneumonia	77	Hospital Ward	1 sachet of probiotics once a day for 7 days	No difference in heart rate, respiratory rate, temperature, presence of retractions or hospital LOS.	Some
Abbreviations: bCPAP: bubble continuous positive airway pressure; CI: confidence interval; IQR: interquartile range; IRR: incidence rate ratio; LOS: length-of-stay; RDAI: respiratory distress assessment instrument									



723 End

1 **Figure 1. PRISMA flow diagram for systematic review.**




medRxiv preprint doi: <https://doi.org/10.1101/2023.01.19.23284769>; this version posted January 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

2

3 **Figure 2. Summary of risk of bias assessments for included randomized-controlled trials**  
 4 **using Cochrane risk-of-bias tool for randomized trials version 2 (RoB 2).**


5

6



7


8 **Figure 3. Consensus judgements on risk of bias for each included study. Each risk of bias**  
 9 **item is assigned a color-coded ranking; green color represents low risk of bias, yellow some**  
 10 **concerns, and red high risk of bias.**  
 11



medRxiv preprint doi: <https://doi.org/10.1101/2023.01.19.23284769>; this version posted January 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

14 **Figure 4. Summary of risk of bias assessments for included non-randomized studies according to**  
 15 **the ROBINS-I tool.**

16



17  
 18  
 19

medRxiv preprint doi: <https://doi.org/10.1101/2023.01.19.23284769>; this version posted January 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

20 **Figure 5. Consensus judgements using Cochrane ROBINS-I for each included nonrandomized**  
 21 **study. Each risk of bias item is assigned a color-coded ranking; green color represents low risk of**  
 22 **bias, yellow some concerns, and red high risk of bias.**

23  
 24  
 25

Study	Risk of bias domains							Overall
	D1	D2	D3	D4	D5	D6	D7	
Adhikari 2016	⊗	-	-	+	+	-	+	⊗
Duke 2001	+	+	+	-	-	-	-	-
Duke 2008	-	-	+	+	-	+	+	-
Hoffman 2019	-	-	-	+	+	-	+	-
Kumar 1997	+	+	+	+	+	+	+	+
Machen 2015	-	+	+	+	+	+	+	-
Shankar 2019	-	-	-	⊗	+	-	+	-

Domains:  
 D1: Bias due to confounding.  
 D2: Bias due to selection of participants.  
 D3: Bias in classification of interventions.  
 D4: Bias due to deviations from intended interventions.  
 D5: Bias due to missing data.  
 D6: Bias in measurement of outcomes.  
 D7: Bias in selection of the reported result.

Judgement  
 ⊗ Serious  
 - Moderate  
 + Low

26